R. A. Abbott, M. Cox, H. Markus, and A. Tomkins, Diet, body size and micronutrient status in Parkinson's disease, Eur. J. Clin. Nutr, vol.46, pp.879-884, 1992.

R. D. Abbott, H. Petrovitch, L. R. White, K. H. Masaki, C. M. Tanner et al., Frequency of bowel movements and the future risk of Parkinson's disease, Neurology, vol.57, pp.456-462, 2001.

R. Abdullah, I. Basak, K. S. Patil, G. Alves, J. P. Larsen et al., Parkinson's disease and age: The obvious but largely unexplored link, Exp. Gerontol, vol.68, pp.33-38, 2015.

A. Abizaid, Z. Liu, Z. B. Andrews, M. Shanabrough, E. Borok et al., Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite, J. Clin. Invest, vol.116, pp.3229-3239, 2006.

L. Abramson and M. Seligman, Modeling psychopathology in the laboratory: history and rationale, pp.1-26, 1977.

C. H. Adler, T. G. Beach, J. G. Hentz, H. A. Shill, J. N. Caviness et al., Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study, Neurology, vol.83, pp.406-412, 2014.

D. Agamonis, Chapter 9 Degenerative diseases

, Neuropathol. Illus. Interact. Course Med. Stud. Resid. URL, vol.16, issue.9

S. L. Alberico, M. D. Cassell, and N. S. Narayanan, The Vulnerable Ventral Tegmental Area in Parkinson's Disease, Basal Ganglia, vol.5, pp.51-55, 2015.

T. Alberio and M. Fasano, Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies, J. Biotechnol, vol.156, pp.325-337, 2011.

R. L. Albin, A. B. Young, and J. B. Penney, The functional anatomy of basal ganglia disorders, Trends Neurosci, vol.12, pp.366-375, 1989.

I. Aldecoa, J. Navarro-otano, N. Stefanova, F. S. Sprenger, K. Seppi et al., Alpha-synuclein immunoreactivity patterns in the enteric nervous system, Neurosci. Lett, vol.602, pp.145-149, 2015.

O. Al-massadi, A. B. Crujeiras, R. C. Gonzalez, M. Pardo, C. Dieguez et al., Age, sex, and lactating status regulate ghrelin secretion and GOAT mRNA levels from isolated rat stomach, AJP Endocrinol. Metab, vol.299, 2010.

D. Alvarez-fischer, S. Guerreiro, S. Hunot, F. Saurini, M. Marien et al., Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid, J. Neurochem, vol.107, pp.701-711, 2008.

H. Alzahrani and A. Venneri, Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson's disease: A systematic review, J. Neurol. Sci, vol.356, pp.32-44, 2015.

W. R. Amberson, H. Penfield, and . Jasper, Epilepsy and the Functional Anatomy of the Human Brain, Science, vol.896, pp.645-646, 1954.

A. D. Andersen, M. Binzer, E. Stenager, and J. B. Gramsbergen, Cerebrospinal fluid biomarkers for Parkinson's disease -a systematic review, Acta Neurol. Scand, 2016.

Z. B. Andrews, D. Erion, R. Beiler, Z. Liu, A. Abizaid et al., Ghrelin Promotes and Protects Nigrostriatal Dopamine Function via a UCP2-Dependent Mitochondrial Mechanism, J. Neurosci, vol.29, pp.14057-14065, 2009.

Z. B. Andrews, Z. Liu, N. Walllingford, D. M. Erion, E. Borok et al., UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals, Nature, vol.454, pp.846-851, 2008.

S. V. Angeloni, N. Glynn, G. Ambrosini, M. J. Garant, J. D. Higley et al., Characterization of the rhesus monkey ghrelin gene and factors influencing ghrelin gene expression and fasting plasma levels, Endocrinology, vol.145, pp.2197-2205, 2004.

P. Anglade, S. Vyas, E. C. Hirsch, and Y. Agid, Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging, Histol. Histopathol, vol.12, pp.603-610, 1997.

E. Angot, J. A. Steiner, C. M. Lema-tomé, P. Ekström, B. Mattsson et al., Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo, PloS One, vol.7, p.39465, 2012.

S. Appel-cresswell, C. Vilarino-guell, M. Encarnacion, H. Sherman, I. Yu et al., Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease, Mov. Disord. Off. J. Mov. Disord. Soc, vol.28, pp.811-813, 2013.

A. Asakawa, A. Inui, M. Fujimiya, R. Sakamaki, N. Shinfuku et al., Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin, Gut, vol.54, pp.18-24, 2005.

A. Asakawa, A. Inui, T. Kaga, H. Yuzuriha, T. Nagata et al., A role of ghrelin in neuroendocrine and behavioral responses to stress in mice, Neuroendocrinology, vol.74, pp.143-147, 2001.

A. Ascherio, H. Chen, M. A. Schwarzschild, S. M. Zhang, G. A. Colditz et al., Caffeine, postmenopausal estrogen, and risk of Parkinson's disease, Neurology, vol.60, pp.790-795, 2003.

F. Assogna, L. Cravello, M. D. Orfei, N. Cellupica, C. Caltagirone et al., Alexithymia in Parkinson's disease: A systematic review of the literature, Parkinsonism Relat. Disord, vol.28, pp.1-11, 2016.

S. Auli?, T. T. Le, F. Moda, S. Abounit, S. Corvaglia et al., Defined ?-synuclein prion-like molecular assemblies spreading in cell culture, BMC Neurosci, vol.15, p.69, 2014.

P. K. Auluck, G. Caraveo, and S. Lindquist, ?-Synuclein: membrane interactions and toxicity in Parkinson's disease, Annu. Rev. Cell Dev. Biol, vol.26, pp.211-233, 2010.

M. Avoli, J. L. Noebels, M. Avoli, M. A. Rogawski, R. W. Olsen et al., Jasper and the Basic Mechanisms of the Epilepsies, National Center for Biotechnology Information (US), 2012.

H. Bagheri, C. Damase-michel, M. Lapeyre-mestre, S. Cismondo, D. O'connell et al., A study of salivary secretion in Parkinson's disease, Clin. Neuropharmacol, vol.22, pp.213-215, 1999.

L. Bahnassawy, S. Nicklas, T. Palm, I. Menzl, F. Birzele et al., The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells, Stem Cells Dev, vol.22, pp.2487-2496, 2013.

G. Baldanzi, Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT, J. Cell Biol, vol.159, pp.1029-1037, 2002.

G. Baldanzi, N. Filigheddu, S. Cutrupi, F. Catapano, S. Bonissoni et al., Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT, J. Cell Biol, vol.159, pp.1029-1037, 2002.

A. Bali and A. S. Jaggi, An Integrative Review on Role and Mechanisms of Ghrelin in Stress, Anxiety and Depression, Curr. Drug Targets, vol.17, pp.495-507, 2016.

R. Bandopadhyay, A. E. Kingsbury, M. R. Cookson, A. R. Reid, I. M. Evans et al., The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease, Brain J. Neurol, vol.127, pp.420-430, 2004.

U. Bandyopadhyay, U. Bandhyopadhyay, and A. M. Cuervo, Chaperone-mediated autophagy in aging and neurodegeneration: lessons from alpha-synuclein, Exp. Gerontol, vol.42, pp.120-128, 2007.

W. A. Banks, Extent and Direction of Ghrelin Transport Across the Blood-Brain Barrier Is Determined by Its Unique Primary Structure, J. Pharmacol. Exp. Ther, vol.302, pp.822-827, 2002.

R. Barazzoni, M. Zanetti, C. Ferreira, P. Vinci, A. Pirulli et al., Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome, J. Clin. Endocrinol. Metab, vol.92, pp.3935-3940, 2007.

A. Barbeau, The pathogenesis of Parkinson's disease: a new hypothesis, Can. Med. Assoc. J, vol.87, pp.802-807, 1962.

T. Barberi, P. Klivenyi, N. Y. Calingasan, H. Lee, H. Kawamata et al., Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice, Nat. Biotechnol, vol.21, pp.1200-1207, 2003.

A. L. Bartels, A. T. Willemsen, R. Kortekaas, B. M. De-jong, R. De-vries et al., Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA, J. Neural Transm, vol.115, pp.1001-1009, 1996.

P. Baskin and J. Salamone, Vacuous jaw movements in rats induced by acute reserpine administration: interactions with different doses of apomorphine, Pharmacol. Biochem. Behav, vol.46, pp.793-797, 1993.

J. A. Bayliss and Z. B. Andrews, Ghrelin is neuroprotective in Parkinson's disease: molecular mechanisms of metabolic neuroprotection, Ther. Adv. Endocrinol. Metab, vol.4, pp.25-36, 2013.

J. A. Bayliss, M. Lemus, V. V. Santos, M. Deo, J. Elsworth et al., Acylated but not des-acyl ghrelin is neuroprotective in an MPTP mouse model of Parkinson's Disease, J. Neurochem, 2016.

J. A. Bayliss, M. B. Lemus, R. Stark, V. V. Santos, A. Thompson et al., Ghrelin-AMPK Signaling Mediates the Neuroprotective Effects of Calorie Restriction in Parkinson's Disease, J. Neurosci. Off. J. Soc. Neurosci, vol.36, pp.3049-3063, 2016.

D. Bega and C. Zadikoff, Complementary & Alternative Management of Parkinson's Disease: An Evidence-Based Review of Eastern Influenced Practices, J. Mov. Disord, vol.7, pp.57-66, 2014.

C. G. Begley, An unappreciated challenge to oncology drug discovery: pitfalls in preclinical research, Am. Soc. Clin. Oncol. Educ. Book ASCO Am. Soc. Clin. Oncol. Meet, pp.466-468, 2013.

C. G. Begley, Six red flags for suspect work, Nature, vol.497, pp.433-434, 2013.

C. G. Begley and L. M. Ellis, Drug development: Raise standards for preclinical cancer research, Nature, vol.483, pp.531-533, 2012.

M. Bélanger and P. J. Magistretti, The role of astroglia in neuroprotection, Dialogues Clin. Neurosci, vol.11, pp.281-295, 2009.

C. Belzung and M. Lemoine, Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression, Biol. Mood Anxiety Disord, vol.1, p.9, 2011.
URL : https://hal.archives-ouvertes.fr/halshs-00792412

A. L. Benabid, P. Pollak, C. Gervason, D. Hoffmann, D. M. Gao et al., Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus, Lancet Lond. Engl, vol.337, pp.403-406, 1991.

A. L. Benabid, P. Pollak, C. Gross, D. Hoffmann, A. Benazzouz et al., Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease, Stereotact. Funct. Neurosurg, vol.62, pp.76-84, 1994.

A. L. Benabid, P. Pollak, A. Louveau, S. Henry, and J. De-rougemont, Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease, Appl. Neurophysiol, vol.50, pp.344-346, 1987.

A. Bender, K. J. Krishnan, C. M. Morris, G. A. Taylor, A. K. Reeve et al., High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease, Nat. Genet, vol.38, pp.515-517, 2006.

A. Benso, D. H. St-pierre, F. Prodam, E. Gramaglia, R. Granata et al., Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans, Eur. J. Endocrinol. Eur. Fed. Endocr. Soc, vol.166, pp.911-916, 2012.

H. Bernheimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger, Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations, J. Neurol. Sci, vol.20, pp.415-455, 1973.

A. Bertler and E. Rosengren, Occurrence and distribution of dopamine in brain and other tissues, Experientia, vol.15, pp.10-11, 1959.

R. Betarbet, T. B. Sherer, G. Mackenzie, M. Garcia-osuna, A. V. Panov et al., Chronic systemic pesticide exposure reproduces features of Parkinson's disease, Nat. Neurosci, vol.3, pp.1301-1306, 2000.

J. Bethlem, . Den-hartog, and W. A. Jager, The incidence and characteristics of Lewy bodies in idiopathic paralysis agitans (Parkinson's disease), J. Neurol. Neurosurg. Psychiatry, vol.23, pp.74-80, 1960.

R. Bhidayasiri and D. Tarsy, Parkinson's Disease: Hoehn and Yahr Scale, Movement Disorders: A Video Atlas, Current Clinical Neurology, pp.4-5, 2012.

R. Bhidayasiri and D. D. Truong, Therapeutic strategies for nonmotor symptoms in early Parkinson's disease: the case for a higher priority and stronger evidence, Parkinsonism Relat. Disord, vol.18, issue.1, pp.110-113, 2012.

J. L. Biedler, L. Helson, and B. A. Spengler, Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture, Cancer Res, vol.33, pp.2643-2652, 1973.

H. Birkmayer, The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia, Wien Klin Wochenschr, vol.10, pp.787-795, 1961.

F. Blandini and M. Armentero, Dopamine receptor agonists for Parkinson's disease, Expert Opin. Investig. Drugs, vol.23, pp.387-410, 2014.

K. Blennow, L. Biscetti, P. Eusebi, and L. Parnetti, Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice, Mov. Disord. Off. J. Mov. Disord. Soc, vol.31, pp.836-847, 2016.

J. Blesa, S. Phani, V. Jackson-lewis, and S. Przedborski, Classic and New Animal Models of Parkinson's Disease, J. Biomed. Biotechnol, vol.2012, pp.1-10, 2012.

J. Blesa, C. Pifl, M. A. Sánchez-gonzález, C. Juri, M. A. García-cabezas et al., The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study, Neurobiol. Dis, vol.48, pp.79-91, 2012.

J. Blesa and S. Przedborski, Parkinson's disease: animal models and dopaminergic cell vulnerability, Front. Neuroanat, vol.8, p.155, 2014.

B. R. Bloem, N. M. De-vries, and G. Ebersbach, Nonpharmacological treatments for patients with Parkinson's disease, Mov. Disord, vol.30, pp.1504-1520, 2015.

A. M. Bonnet, M. F. Jutras, V. Czernecki, J. C. Corvol, and M. Vidailhet, Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects, 2012.

J. Booij, J. D. Speelman, M. W. Horstink, and E. C. Wolters, The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism, Eur. J. Nucl. Med, vol.28, pp.266-272, 2001.

H. Braak and E. Braak, Cognitive impairment in Parkinson's disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex, J. Neural Transm. Park. Dis. Dement. Sect, vol.2, pp.45-57, 1990.

H. Braak, R. A. De-vos, E. N. Jansen, H. Bratzke, and E. Braak, Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog, Brain Res, vol.117, pp.267-285, 1998.

H. Braak, R. A. De-vos, J. Bohl, and K. Del-tredici, Gastric ?-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology, Neurosci. Lett, vol.396, pp.67-72, 2006.

H. Braak, E. Ghebremedhin, U. Rüb, H. Bratzke, and K. Tredici, Stages in the development of Parkinson's disease-related pathology, Cell Tissue Res, vol.318, pp.121-134, 2004.

H. Braak, K. D. Tredici, U. Rüb, R. A. De-vos, E. N. Jansen-steur et al., Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol. Aging, vol.24, pp.197-211, 2003.

J. Bradbury, ?-synuclein gene triplication discovered in Parkinson's disease, Lancet Neurol, vol.2, p.715, 2003.

E. Braungart, M. Gerlach, P. Riederer, R. Baumeister, and M. C. Hoener, Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings, Neurodegener. Dis, vol.1, pp.175-183, 2004.

S. Breid, M. E. Bernis, J. T. Babila, M. C. Garca, H. Wille et al., Neuroinvasion of ?-Synuclein Prionoids after Intraperitoneal and Intraglossal Inoculation, J. Virol, 2016.

T. Breidert, J. Callebert, M. T. Heneka, G. Landreth, J. M. Launay et al., Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease, J. Neurochem, vol.82, pp.615-624, 2002.

V. Brochard, B. Combadière, A. Prigent, Y. Laouar, A. Perrin et al., Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease, J. Clin. Invest, vol.119, pp.182-192, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00393947

F. Broglio, C. Gottero, F. Prodam, C. Gauna, G. Muccioli et al., Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans, J. Clin. Endocrinol. Metab, vol.89, pp.3062-3065, 2004.

F. Broglio, C. Gottero, F. Prodam, C. Gauna, G. Muccioli et al., Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans, J. Clin. Endocrinol. Metab, vol.89, pp.3062-3065, 2004.

A. I. Brooks, C. A. Chadwick, H. A. Gelbard, D. A. Cory-slechta, and H. J. Federoff, Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss, Brain Res, vol.823, pp.1-10, 1999.

E. Broussolle, F. Borson, J. M. Gonzalez-de-suso, J. A. Chayvialle, M. Beylot et al., Rev. Neurol, vol.147, pp.46-51, 1991.

D. Brück, G. K. Wenning, N. Stefanova, and L. Fellner, Glia and alpha-synuclein in neurodegeneration: A complex interaction, Neurobiol. Dis, vol.85, pp.262-274, 2016.

I. Bulgarelli, L. Tamiazzo, E. Bresciani, D. Rapetti, S. Caporali et al., Desacyl-ghrelin and synthetic GH-secretagogues modulate the production of inflammatory cytokines in mouse microglia cells stimulated by beta-amyloid fibrils, J. Neurosci. Res, vol.87, pp.2718-2727, 2009.

D. J. Burn, E. N. Rowan, L. M. Allan, S. Molloy, J. T. O'brien et al., Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies, J. Neurol. Neurosurg. Psychiatry, vol.77, pp.585-589, 2006.

J. Burré, M. Sharma, T. Tsetsenis, V. Buchman, M. R. Etherton et al., Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro, Science, vol.329, pp.1663-1667, 2010.

Z. I. Cabantchik, A. Munnich, M. B. Youdim, and D. Devos, Regional siderosis: a new challenge for iron chelation therapy, Front. Pharmacol, vol.4, 2013.

A. Cabral, G. Fernandez, and M. Perello, Analysis of brain nuclei accessible to ghrelin present in the cerebrospinal fluid, Neuroscience, vol.253, pp.406-415, 2013.

B. Callaghan and J. B. Furness, Novel and Conventional Receptors for Ghrelin, Desacyl-Ghrelin, and Pharmacologically Related Compounds, Pharmacol. Rev, vol.66, pp.984-1001, 2014.

M. B. Callesen, J. Scheel-krüger, M. L. Kringelbach, and A. Møller, A systematic review of impulse control disorders in Parkinson's disease, J. Park. Dis, vol.3, pp.105-138, 2013.

J. P. Camiña, M. Lodeiro, O. Ischenko, A. C. Martini, and F. F. Casanueva, Stimulation by ghrelin of p42/p44 mitogen-activated protein kinase through the GHS-R1a receptor: role of G-proteins and beta-arrestins, J. Cell. Physiol, vol.213, pp.187-200, 2007.

V. P. Carlini, M. E. Monzón, M. M. Varas, A. B. Cragnolini, H. B. Schiöth et al., Ghrelin increases anxiety-like behavior and memory retention in rats, Biochem. Biophys. Res. Commun, vol.299, pp.739-743, 2002.

A. Carlsson, M. Lindqvist, and T. Magnusson, 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists, Nature, vol.180, p.1200, 1957.

A. Carlsson, M. Lindqvist, T. Magnusson, and B. Waldeck, On the presence of 3-hydroxytyramine in brain, Science, vol.127, p.471, 1958.

M. Carta, T. Carlsson, A. Muñoz, D. Kirik, and A. Björklund, Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias, Prog. Brain Res, vol.172, pp.465-478, 2008.

W. M. Caudle, R. E. Colebrooke, P. C. Emson, and G. W. Miller, Altered vesicular dopamine storage in Parkinson's disease: a premature demise, Trends Neurosci, vol.31, pp.303-308, 2008.

M. Cazorla, F. D. De-carvalho, M. O. Chohan, M. Shegda, N. Chuhma et al., Dopamine D2 receptors regulate the anatomical and functional balance of basal ganglia circuitry, Neuron, vol.81, pp.153-164, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02438087

J. S. Chandran, X. Lin, A. Zapata, A. Höke, M. Shimoji et al., Progressive behavioral deficits in DJ-1-deficient mice are associated with normal nigrostriatal function, Neurobiol. Dis, vol.29, pp.505-514, 2008.

M. Chartier-harlin, J. C. Dachsel, C. Vilariño-güell, S. J. Lincoln, F. Leprêtre et al., Translation initiator EIF4G1 mutations in familial Parkinson disease, Am. J. Hum. Genet, vol.89, pp.398-406, 2011.

M. Chartier-harlin, J. Kachergus, C. Roumier, V. Mouroux, X. Douay et al., ?-synuclein locus duplication as a cause of familial Parkinson's disease, The Lancet, vol.364, pp.1167-1169, 2004.

K. Chaudhuri and A. H. Schapira, Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment, Lancet Neurol, vol.8, pp.464-474, 2009.

K. R. Chaudhuri, D. G. Healy, and A. H. Schapira, Nonmotor symptoms of Parkinson's disease: diagnosis and management, Lancet Neurol, vol.5, pp.235-245, 2006.

C. Chen, Y. Weng, K. Chien, K. Lin, T. Yeh et al., G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD, Cell Death Differ, vol.19, pp.1623-1633, 2012.

H. Chen, S. M. Zhang, M. A. Hernán, M. A. Schwarzschild, W. C. Willett et al., Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease, Arch. Neurol, vol.60, pp.1059-1064, 2003.

M. Chesselet, In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?, Exp. Neurol, vol.209, pp.22-27, 2008.

M. Chesselet, F. Richter, C. Zhu, I. Magen, M. B. Watson et al., A Progressive Mouse Model of Parkinson's Disease: The Thy1-aSyn, Neurotherapeutics, vol.9, pp.297-314, 2012.

Z. H. Cheung and N. Y. Ip, The emerging role of autophagy in Parkinson's disease, Mol. Brain, vol.2, p.29, 2009.

K. Chiba, L. A. Peterson, K. P. Castagnoli, A. J. Trevor, and N. Castagnoli, Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Drug Metab. Dispos. Biol. Fate Chem, vol.13, pp.342-347, 1985.

K. Chiba, A. Trevor, and N. Castagnoli, Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase, Biochem. Biophys. Res. Commun, vol.120, pp.574-578, 1984.

C. C. Chiueh, S. P. Markey, R. S. Burns, J. N. Johannessen, A. Pert et al., Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat, Eur. J. Pharmacol, vol.100, pp.189-194, 1984.

K. B. Chow, J. Sun, K. Chu, W. Tai-cheung, C. H. Cheng et al., The truncated ghrelin receptor polypeptide (GHS-R1b) is localized in the endoplasmic reticulum where it forms heterodimers with ghrelin receptors (GHS-R1a) to attenuate their cell surface expression, Mol. Cell. Endocrinol, vol.348, pp.247-254, 2012.

L. J. Cloud and J. G. Greene, Gastrointestinal Features of Parkinson's Disease, Curr. Neurol. Neurosci. Rep, vol.11, pp.379-384, 2011.

F. C. Colpaert, Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat, Neuropharmacology, vol.26, pp.1431-1440, 1987.

B. Connolly and S. H. Fox, Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease, Neurother. J. Am. Soc. Exp. Neurother, vol.11, pp.78-91, 2014.

J. Corcuff, E. Krim, F. Tison, A. Foubert-sanier, D. Guehl et al., Subthalamic nucleus stimulation in patients with Parkinson's disease does not increase serum ghrelin levels, Br. J. Nutr, vol.95, pp.1028-1029, 2006.

J. L. Costa, D. Naot, J. Lin, M. Watson, K. E. Callon et al., Ghrelin is an Osteoblast Mitogen and Increases Osteoclastic Bone Resorption In Vitro, Int. J. Pept, p.605193, 2011.

G. C. Cotzias, M. H. Van-woert, and L. M. Schiffer, Aromatic amino acids and modification of parkinsonism, N. Engl. J. Med, vol.276, pp.374-379, 1967.

M. A. Cowley, R. G. Smith, S. Diano, M. Tschöp, N. Pronchuk et al., The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis, Neuron, vol.37, pp.649-661, 2003.

A. M. Cuervo, L. Stefanis, R. Fredenburg, P. T. Lansbury, and D. Sulzer, Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy, Science, vol.305, pp.1292-1295, 2004.

D. E. Cummings, J. Q. Purnell, R. S. Frayo, K. Schmidova, B. E. Wisse et al., A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans, Diabetes, vol.50, pp.1714-1719, 2001.

P. Damier, E. C. Hirsch, P. Zhang, Y. Agid, and F. Javoy-agid, Glutathione peroxidase, glial cells and Parkinson's disease, Neuroscience, vol.52, pp.1-6, 1993.

Y. Date, M. Nakazato, N. Murakami, M. Kojima, K. Kangawa et al., Ghrelin Acts in the Central Nervous System to Stimulate Gastric Acid Secretion, Biochem. Biophys. Res. Commun, vol.280, pp.904-907, 2001.

W. Dauer and S. Przedborski, Parkinson's disease: mechanisms and models, Neuron, vol.39, pp.889-909, 2003.

K. D. Dave, S. De-silva, N. P. Sheth, S. Ramboz, M. J. Beck et al., Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease, Neurobiol. Dis, vol.70, pp.190-203, 2014.

G. P. Davey, K. F. Tipton, and M. P. Murphy, Uptake and accumulation of 1-methyl-4-phenylpyridinium by rat liver mitochondria measured using an ion-selective electrode, Biochem. J, vol.288, pp.439-443, 1992.

G. C. Davis, A. C. Williams, S. P. Markey, M. H. Ebert, E. D. Caine et al., Chronic Parkinsonism secondary to intravenous injection of meperidine analogues, Psychiatry Res, vol.1, pp.249-254, 1979.

B. J. Day, M. Patel, L. Calavetta, L. Y. Chang, and J. S. Stamler, A mechanism of paraquat toxicity involving nitric oxide synthase, Proc. Natl. Acad. Sci. U. S. A, vol.96, pp.12760-12765, 1999.

M. De-rijk, C. Tzourio, M. M. Breteler, J. F. Dartigues, L. Amaducci et al., Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, vol.62, pp.10-15, 1997.

B. Dehay, J. Bové, N. Rodríguez-muela, C. Perier, A. Recasens et al., Pathogenic Lysosomal Depletion in Parkinson's Disease, J. Neurosci, vol.30, pp.12535-12544, 2010.

P. J. Delhanty, S. J. Neggers, and A. J. Van-der-lely, Des-acyl ghrelin: a metabolically active peptide, Endocr. Dev, vol.25, pp.112-121, 2013.

P. J. Delhanty, Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a, J. Endocrinol, vol.188, pp.37-47, 2006.

P. J. Delhanty, M. Huisman, M. Julien, K. Mouchain, P. Brune et al., The acylated (AG) to unacylated (UAG) ghrelin ratio in esterase inhibitortreated blood is higher than previously described, Clin. Endocrinol. (Oxf.), vol.82, pp.142-146, 2015.

P. J. Delhanty, S. J. Neggers, and A. J. Van-der-lely, Should we consider des-acyl ghrelin as a separate hormone and if so, what does it do?, Front. Horm. Res, vol.42, pp.163-174, 2014.

M. R. Delong, Primate models of movement disorders of basal ganglia origin, Trends Neurosci, vol.13, pp.281-285, 1990.

C. Delporte, Structure and Physiological Actions of Ghrelin. Scientifica, vol.2013, pp.1-25, 2013.

P. Derkinderen, T. Rouaud, T. Lebouvier, S. B. Des-varannes, M. Neunlist et al., Parkinson disease The enteric nervous system spills its guts, Neurology, vol.77, pp.1761-1767, 2011.

S. Desagher, J. Glowinski, and J. Premont, Astrocytes protect neurons from hydrogen peroxide toxicity, J. Neurosci, vol.16, pp.2553-2562, 1996.

P. Desplats, H. Lee, E. Bae, C. Patrick, E. Rockenstein et al., Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein, Proc. Natl. Acad. Sci. U. S. A, vol.106, pp.13010-13015, 2009.

U. Dettmer, A. J. Newman, V. E. Von-saucken, T. Bartels, and D. Selkoe, KTKEGV repeat motifs are key mediators of normal ?-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity, Proc. Natl. Acad. Sci. U. S. A, vol.112, pp.9596-9601, 2015.

D. Devos, C. Moreau, J. C. Devedjian, J. Kluza, M. Petrault et al., Targeting chelatable iron as a therapeutic modality in Parkinson's disease, Antioxid. Redox Signal, vol.21, pp.195-210, 2014.

S. Diano, S. Farr, S. .. Benoit, E. Mcnay, I. Da-silva et al., Ghrelin controls hippocampal spine synapse density and memory prformance, Nat. Neurosci, vol.9, pp.381-388, 2006.

V. Dias, E. Junn, and M. M. Mouradian, The Role of Oxidative Stress in Parkinson's Disease, J. Park. Dis, vol.3, pp.461-491, 2013.

D. W. Dickson, Parkinson's Disease and Parkinsonism: Neuropathology. Cold Spring Harb, Perspect. Med, vol.2, p.9258, 2012.

D. W. Dickson, H. Braak, J. E. Duda, C. Duyckaerts, T. Gasser et al., Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria, Lancet Neurol, vol.8, pp.70238-70246, 2009.

N. N. Dissanayaka, A. Sellbach, S. Matheson, J. D. O'sullivan, P. A. Silburn et al., Anxiety disorders in Parkinson's disease: prevalence and risk factors, Mov. Disord. Off. J. Mov. Disord. Soc, vol.25, pp.838-845, 2010.

C. B. Do, J. Y. Tung, E. Dorfman, A. K. Kiefer, E. M. Drabant et al., Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease, PLoS Genet, vol.7, p.1002141, 2011.

J. Dong, N. Song, J. Xie, and H. Jiang, Ghrelin Antagonized 1-Methyl-4-Phenylpyridinium (MPP+)-Induced Apoptosis in MES23.5 Cells, J. Mol. Neurosci, vol.37, pp.182-189, 2009.

E. R. Dorsey, R. Constantinescu, J. P. Thompson, K. M. Biglan, R. G. Holloway et al., Projected number of people with Parkinson disease in the most populous nations, Neurology, vol.68, pp.384-386, 2005.

E. R. Dorsey, B. P. George, B. Leff, and A. W. Willis, The coming crisis, Neurology, vol.80, 1989.

R. L. Doty, Olfactory dysfunction in Parkinson disease, Nat. Rev. Neurol, vol.8, pp.329-339, 2012.

W. Duan and M. P. Mattson, Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease, J. Neurosci. Res, vol.57, pp.195-206, 1999.

S. B. Dunnett and M. Lelos, Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson's disease. Prog, Brain Res, vol.184, issue.10, pp.84003-84011, 2010.

C. J. Dunning, J. F. Reyes, J. A. Steiner, and P. Brundin, Can Parkinson's disease pathology be propagated from one neuron to another?, Prog. Neurobiol, vol.97, pp.205-219, 2012.

J. Dusonchet, O. Kochubey, K. Stafa, S. M. Young, R. Zufferey et al., A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2, J. Neurosci. Off. J. Soc. Neurosci, vol.31, pp.907-912, 2011.

S. Duty and P. Jenner, Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease: Animal models of Parkinson's disease, Br. J. Pharmacol, vol.164, pp.1357-1391, 2011.

R. C. Duvoisin, R. Eldridge, A. Williams, J. Nutt, and D. Calne, Twin study of Parkinson disease, Neurology, vol.31, pp.77-77, 1981.

M. J. Eadie and J. H. Tyrer, ALIMENTARY DISORDER IN PARKINSONISM, Australas. Ann. Med, vol.14, pp.13-22, 1965.

S. Edvardson, Y. Cinnamon, A. Ta-shma, A. Shaag, Y. Yim et al., A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism, PloS One, vol.7, 2012.

L. L. Edwards, R. F. Pfeiffer, E. M. Quigley, R. Hofman, and M. Balluff, Gastrointestinal symptoms in Parkinson's disease, Mov. Disord. Off. J. Mov. Disord. Soc, vol.6, pp.151-156, 1991.

T. L. Edwards, W. K. Scott, C. Almonte, A. Burt, E. H. Powell et al., Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease, Ann. Hum. Genet, vol.74, pp.97-109, 2010.

H. Ehringer and O. Hornykiewicz, Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system, 1960.

, Klin. Wochenschr, vol.38, pp.1236-1239

T. Eichner and S. E. Radford, A diversity of assembly mechanisms of a generic amyloid fold, Mol. Cell, vol.43, pp.8-18, 2011.

E. Eidelberg, B. A. Brooks, W. W. Morgan, J. G. Walden, and R. H. Kokemoor, Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys, Neuroscience, vol.18, pp.817-822, 1986.

P. Ejlerskov, I. Rasmussen, T. T. Nielsen, A. Bergström, Y. Tohyama et al., Tubulin polymerization-promoting protein (TPPP/p25?) promotes unconventional secretion of ?-synuclein through exophagy by impairing autophagosome-lysosome fusion, J. Biol. Chem, vol.288, pp.17313-17335, 2013.

N. Ejskjaer, G. Dimcevski, J. Wo, P. M. Hellström, L. C. Gormsen et al., Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study, Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc, vol.22, pp.1069-281, 2010.

N. Ejskjaer, J. M. Wo, T. Esfandyari, M. Jamal, G. Dimcevski et al., A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis, Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc, vol.25, pp.140-150, 2013.

A. Elbaz, L. Carcaillon, S. Kab, and F. Moisan, Epidemiology of Parkinson's disease, Rev. Neurol, vol.172, pp.14-26, 2016.

R. Eldridge and S. E. Ince, The low concordance rate for Parkinson's disease in twins A possible explanation, Neurology, vol.34, pp.1354-1354, 1984.

J. D. Erickson, L. E. Eiden, M. K. Schafer, and E. Weihe, Reserpine-and tetrabenazine-sensitive transport of (3)H-histamine by the neuronal isoform of the vesicular monoamine transporter, J. Mol. Neurosci. MN, vol.6, pp.277-287, 1995.

A. H. Evans, A. D. Lawrence, J. Potts, L. Macgregor, R. Katzenschlager et al., Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, vol.77, pp.317-321, 2006.

G. Fabbrini, J. M. Brotchie, F. Grandas, M. Nomoto, and C. G. Goetz, Levodopa-induced dyskinesias, Mov. Disord. Off. J. Mov. Disord. Soc, vol.22, pp.1379-1389, 2007.

S. Fahn, The medical treatment of Parkinson disease from James Parkinson to George Cotzias, Mov. Disord. Off. J. Mov. Disord. Soc, vol.30, pp.4-18, 2015.

B. H. Falkenburger, T. Saridaki, and E. Dinter, Cellular models for Parkinson's disease, J. Neurochem, 2016.

B. H. Falkenburger, P. D. Schulz, P. D. Riederer, P. D. Reichmann, P. D. Youdim et al., Limitations of cellular models in Parkinson's disease research, Journal of Neural Transmission. Supplementa, pp.261-268, 2006.

M. Farrer, K. Gwinn-hardy, M. Muenter, F. W. Devrieze, R. Crook et al., A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor, Hum. Mol. Genet, vol.8, pp.81-85, 1999.

M. B. Feany and W. W. Bender, A Drosophila model of Parkinson's disease, Nature, vol.404, pp.394-398, 2000.

F. Fenelon, Neurosurgery of the ansa lenticularis in dyskinesia and Parkinson's disease, 1955.

. Sem and . Hôp, Organe Fondé Par Assoc. Enseign. Méd. Hôp. Paris, vol.31, pp.1835-1837

F. Fenelon, Subpallidal extrapyramidotomy by electrocoagulation in the treatment of dyskinesia, Rev. Esp. Oto-Neuro-Oftalmol. Neurocir, vol.14, pp.99-104, 1955.

R. Ferese, N. Modugno, R. Campopiano, M. Santilli, S. Zampatti et al., Four Copies of SNCA Responsible for Autosomal Dominant Parkinson's Disease in Two Italian Siblings, p.546462, 2015.

V. S. Fernandes, J. R. Santos, A. H. Leão, A. M. Medeiros, T. G. Melo et al., Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's disease, Behav. Brain Res, vol.231, pp.154-163, 2012.

R. J. Ferrante, J. B. Schulz, N. W. Kowall, and M. F. Beal, Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra, Brain Res, vol.753, pp.157-162, 1997.

U. Fiszer, M. Micha?owska, B. Baranowska, E. Woli?ska-witort, W. Jeske et al., Leptin and ghrelin concentrations and weight loss in Parkinson's disease, Acta Neurol. Scand, vol.121, pp.230-236, 2010.

S. M. Fleming, Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human -Synuclein, J. Neurosci, vol.24, pp.9434-9440, 2004.

S. M. Fleming, J. Salcedo, P. Fernagut, E. Rockenstein, E. Masliah et al., Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein, J. Neurosci. Off. J. Soc. Neurosci, vol.24, pp.9434-9440, 2004.

M. S. Forman, J. Q. Trojanowski, V. M. Lee, and .. , Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs, Nat. Med, vol.10, pp.1055-1063, 2004.

J. S. Fowler, N. D. Volkow, G. J. Wang, J. Logan, N. Pappas et al., Agerelated increases in brain monoamine oxidase B in living healthy human subjects, Neurobiol. Aging, vol.18, pp.431-435, 1997.

L. Frago, Neuroprotective actions of ghrelin and growth hormone secretagogues, Front. Mol. Neurosci, vol.4, 2011.

M. François, S. Barde, N. Achamrah, J. Breton, J. Do-rego et al., The number of preproghrelin mRNA expressing cells is increased in mice with activity-based anorexia, Neuropeptides, vol.51, pp.17-23, 2015.

N. E. Fritz, D. A. Kegelmeyer, A. D. Kloos, S. Linder, A. Park et al., Motor performance differentiates individuals with Lewy body dementia, Parkinson's and Alzheimer's disease, Gait Posture, vol.50, pp.1-7, 2016.

M. Funayama, K. Hasegawa, H. Kowa, M. Saito, S. Tsuji et al., A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1, Ann. Neurol, vol.51, pp.296-301, 2002.

M. Funayama, K. Ohe, T. Amo, N. Furuya, J. Yamaguchi et al., CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genomewide linkage and sequencing study, Lancet Neurol, vol.14, issue.14, pp.70266-70268, 2015.

J. B. Furness, B. Hunne, N. Matsuda, L. Yin, D. Russo et al., Investigation of the presence of ghrelin in the central nervous system of the rat and mouse, Neuroscience, vol.193, pp.1-9, 2011.

X. Gao, E. R. Martin, Y. Liu, G. Mayhew, J. M. Vance et al., Genome-wide linkage screen in familial Parkinson disease identifies loci on chromosomes 3 and 18, Am. J. Hum. Genet, vol.84, pp.499-504, 2009.

R. C. Gardner, J. F. Burke, J. Nettiksimmons, S. Goldman, C. M. Tanner et al., Traumatic brain injury in later life increases risk for Parkinson disease, Ann. Neurol, vol.77, pp.987-995, 2015.

T. Gasser, B. Müller-myhsok, Z. K. Wszolek, R. Oehlmann, D. B. Calne et al., A susceptibility locus for Parkinson's disease maps to chromosome 2p13, Nat. Genet, vol.18, pp.262-265, 1998.

C. Gauna, P. J. Delhanty, L. J. Hofland, J. A. Janssen, F. Broglio et al., Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes, J. Clin. Endocrinol. Metab, vol.90, pp.1055-1060, 2005.

C. Gauna, B. Van-de-zande, A. Van-kerkwijk, A. P. Themmen, A. J. Van-der-lely et al., Unacylated ghrelin is not a functional antagonist but a full agonist of the type 1a growth hormone secretagogue receptor (GHS-R), Mol. Cell. Endocrinol, vol.274, pp.30-34, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00531929

F. Gaven, P. Marin, and S. Claeysen, Primary culture of mouse dopaminergic neurons, J. Vis. Exp. JoVE e51751, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01943338

J. F. Geddes, A. J. Hughes, A. J. Lees, and S. E. Daniel, Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. A study of recent cases of postencephalitic parkinsonism and comparison with progressive supranuclear palsy and Guamanian parkinsonism-dementia complex, Brain J. Neurol, vol.116, pp.281-302, 1993.

N. Germain, B. Galusca, D. Grouselle, D. Frere, S. Billard et al., Ghrelin and obestatin circadian levels differentiate bingeing-purging from restrictive anorexia nervosa, J. Clin. Endocrinol. Metab, vol.95, pp.3057-3062, 2010.

N. Germain, B. Galusca, D. Grouselle, D. Frere, V. Tolle et al., Ghrelin/obestatin ratio in two populations with low bodyweight: constitutional thinness and anorexia nervosa, Psychoneuroendocrinology, vol.34, pp.413-419, 2009.

E. Gershon and W. W. Vale, CRF type 2 receptors mediate the metabolic effects of ghrelin in C2C12 cells, Obes. Silver Spring Md, vol.22, pp.380-389, 2014.

E. Ghigo, F. Broglio, E. Arvat, M. Maccario, M. Papotti et al., Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor, Clin. Endocrinol. (Oxf.), vol.62, pp.1-17, 2005.

P. L. Gildenberg, Evolution of basal ganglia surgery for movement disorders, Stereotact. Funct. Neurosurg, vol.84, pp.131-135, 2006.

Y. Glinka, M. Gassen, and M. B. Youdim, Mechanism of 6-hydroxydopamine neurotoxicity, J. Neural Transm. Suppl, vol.50, pp.55-66, 1997.

S. Gnanapavan, B. Kola, S. A. Bustin, D. G. Morris, P. Mcgee et al., The tissue distribution of the mRNA of the ghrelin and subtypes of its receptor, GHS-R, in humans, J. Clin. Endocrinol. Metab, vol.87, pp.2988-2991, 2002.

J. Godau, A. Hussl, P. Lolekha, A. J. Stoessl, and K. Seppi, Neuroimaging: Current role in detecting pre-motor Parkinson's disease, Mov. Disord, vol.27, pp.634-643, 2012.

M. Goedert, M. G. Spillantini, K. Del-tredici, and H. Braak, 100 years of Lewy pathology, Nat. Rev. Neurol, vol.9, pp.13-24, 2013.

C. G. Goetz, The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies. Cold Spring Harb, Perspect. Med, vol.1, pp.8862-008862, 2011.

C. G. Goetz, S. Fahn, P. Martinez-martin, W. Poewe, C. Sampaio et al., Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan, Mov. Disord. Off. J. Mov. Disord. Soc, vol.22, pp.41-47, 2007.

M. S. Goldberg, Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons, J. Biol. Chem, vol.278, pp.43628-43635, 2003.

J. E. Goldman, S. H. Yen, F. C. Chiu, and N. S. Peress, Lewy bodies of Parkinson's disease contain neurofilament antigens, Science, vol.221, pp.1082-1084, 1983.

J. M. Goldstein, A. Barnett, and J. B. Malick, The evaluation of anti-parkinson drugs on reserpineinduced rigidity in rats, Eur. J. Pharmacol, vol.33, pp.183-188, 1975.

R. A. González-polo, M. Niso-santano, M. A. Ortíz-ortíz, A. Gómez-martín, J. M. Morán et al., Relationship between autophagy and apoptotic cell death in human neuroblastoma cells treated with paraquat: could autophagy be a "brake, Autophagy, vol.3, pp.366-367, 2007.

R. A. González-polo, M. Niso-santano, M. A. Ortíz-ortíz, A. Gómez-martín, J. M. Morán et al., Inhibition of paraquat-induced autophagy accelerates the apoptotic cell death in neuroblastoma SH-SY5Y cells, Toxicol. Sci. Off. J. Soc. Toxicol, vol.97, pp.448-458, 2007.

R. Goodman and H. R. Herschman, Nerve growth factor-mediated induction of tyrosine hydroxylase in a clonal pheochromocytoma cell line, Proc. Natl. Acad. Sci. U. S. A, vol.75, pp.4587-4590, 1978.

A. M. Gotham, R. G. Brown, and C. D. Marsden, Depression in Parkinson's disease: a quantitative and qualitative analysis, J. Neurol. Neurosurg. Psychiatry, vol.49, pp.381-389, 1986.

R. Granata, F. Settanni, L. Biancone, L. Trovato, R. Nano et al., Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: involvement of 3',5'-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-Kinase/Akt signaling, Endocrinology, vol.148, pp.512-529, 2007.

C. M. Grau and L. A. Greene, Use of PC12 Cells and Rat Superior Cervical Ganglion Sympathetic Neurons as Models for Neuroprotective Assays Relevant to Parkinson's Disease, Methods Mol. Biol. Clifton NJ, vol.846, pp.201-211, 2012.

M. T. Gray and J. M. Woulfe, Striatal blood-brain barrier permeability in Parkinson's disease, J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab, vol.35, pp.747-750, 2015.

J. T. Greenamyre, T. B. Sherer, R. Betarbet, and A. V. Panov, Complex I and Parkinson's Disease, IUBMB Life, vol.52, pp.135-141, 2001.

J. G. Greenfield and F. D. Bosanquet, The brain-stem lesions in Parkinsonism, J. Neurol. Neurosurg. Psychiatry, vol.16, pp.213-226, 1953.

S. Greffard, M. Verny, A. Bonnet, D. Seilhean, J. Hauw et al., A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death, Neurobiol. Aging, vol.31, pp.99-103, 2010.

R. C. Griggs, B. Fontaine, and G. Sobue, Global imperatives and challenges facing the practice of neurology, Neurol. Clin. Pract, vol.1, pp.49-54, 2011.

C. E. Gross, T. Boraud, D. Guehl, B. Bioulac, and E. Bezard, From experimentation to the surgical treatment of Parkinson's disease: prelude or suite in basal ganglia research?, Prog. Neurobiol, vol.59, pp.509-532, 1999.

X. Guan, H. Yu, O. C. Palyha, K. K. Mckee, S. D. Feighner et al., Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues, Mol. Brain Res, vol.48, pp.23-29, 1997.

G. Guiot and S. Brion, , 1953.

, Rev. Neurol, vol.89, pp.578-580

J. A. Gutierrez, P. J. Solenberg, D. R. Perkins, J. A. Willency, M. D. Knierman et al., Ghrelin octanoylation mediated by an orphan lipid transferase, Proc. Natl. Acad. Sci. 105, pp.6320-6325, 2008.

C. A. Haaxma, B. R. Bloem, G. F. Borm, W. J. Oyen, K. L. Leenders et al., Gender differences in Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, vol.78, pp.819-824, 2007.

A. Haehner, S. Boesveldt, H. W. Berendse, A. Mackay-sim, J. Fleischmann et al., Prevalence of smell loss in Parkinson's disease--a multicenter study, Parkinsonism Relat. Disord, vol.15, pp.490-494, 2009.

S. Halbgebauer, P. Öckl, K. Wirth, P. Steinacker, and M. Otto, Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins, Mov. Disord. Off. J. Mov. Disord. Soc, vol.31, pp.848-860, 2016.

M. Hallett, Parkinson's disease tremor: pathophysiology, Parkinsonism Relat. Disord, vol.18, issue.1, pp.85-86, 2012.

G. Halliday, M. T. Herrero, K. Murphy, H. Mccann, F. Ros-bernal et al., No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism, Mov. Disord. Off. J. Mov. Disord. Soc, vol.24, pp.1519-1523, 2009.

G. M. Halliday, Thalamic changes in Parkinson's disease, Proceedings of WFN XVIII World Congress on Parkinson's Disease and, vol.15, pp.152-155, 2009.

D. J. Hampshire, E. Roberts, Y. Crow, J. Bond, A. Mubaidin et al., Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36, J. Med. Genet, vol.38, pp.680-682, 2001.

T. Hasegawa, M. Matsuzaki, A. Takeda, A. Kikuchi, H. Akita et al., Accelerated alpha-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells, Brain Res, vol.1013, pp.51-59, 2004.

Z. S. Heetun and E. M. Quigley, Gastroparesis and Parkinson's disease: a systematic review, Parkinsonism Relat. Disord, vol.18, pp.433-440, 2012.

M. A. Hely, J. G. Morris, W. G. Reid, and R. Trafficante, Sydney multicenter study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years, Mov. Disord, vol.20, pp.190-199, 2005.

M. A. Hernán, B. Takkouche, F. Caamaño-isorna, and J. J. Gestal-otero, A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease, Ann. Neurol, vol.52, pp.276-284, 2002.

A. A. Hicks, H. Pétursson, T. Jónsson, H. Stefánsson, H. S. Jóhannsdóttir et al., A susceptibility gene for lateonset idiopathic Parkinson's disease, Ann. Neurol, vol.52, pp.549-555, 2002.

T. Hideshima, J. E. Bradner, D. Chauhan, and K. C. Anderson, Intracellular protein degradation and its therapeutic implications, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.11, pp.8530-8533, 2005.

R. Hinde, Animal models in human psychobiology, The Uses of Similarities and Differences in Comparative Psychopathology, pp.187-202, 1976.

Y. Hirata and T. Nagatsu, Rotenone and CCCP inhibit tyrosine hydroxylation in rat striatal tissue slices, Toxicology, vol.216, pp.9-14, 2005.

E. C. Hirsch, S. Hunot, and A. Hartmann, Neuroinflammatory processes in Parkinson's disease, Parkinsonism Relat. Disord, vol.11, 2005.

H. Hoepken, S. Gispert, M. Azizov, M. Klinkenberg, F. Ricciardi et al., Parkinson patient fibroblasts show increased alpha-synuclein expression, Exp. Neurol, vol.212, pp.307-313, 2008.

B. Holdorff, Friedrich Heinrich Lewy (1885-1950) and his work, J. Hist. Neurosci, vol.11, pp.19-28, 2002.

R. G. Holloway, I. Shoulson, S. Fahn, K. Kieburtz, A. Lang et al., Arch. Neurol, vol.61, pp.1044-1053, 2004.

P. Holmans, V. Moskvina, L. Jones, M. Sharma, . Parkinson's-disease-genomics-consortium et al., A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease, Hum. Mol. Genet, vol.22, pp.1039-1049, 2013.

S. Holmqvist, O. Chutna, L. Bousset, P. Aldrin-kirk, W. Li et al., Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats, Acta Neuropathol. (Berl, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01155404

B. Holst, A. Cygankiewicz, T. H. Jensen, M. Ankersen, and T. W. Schwartz, High Constitutive Signaling of the Ghrelin Receptor-Identification of a Potent Inverse Agonist, Mol. Endocrinol, vol.17, pp.2201-2210, 2003.

C. L. Hoppel, D. Grinblatt, H. C. Kwok, P. K. Arora, M. P. Singh et al., Inhibition of mitochondrial respiration by analogs of 4-phenylpyridine and 1-methyl-4-phenylpyridinium cation (MPP+), the neurotoxic metabolite of MPTP, Biochem. Biophys. Res. Commun, vol.148, pp.684-693, 1987.

H. Hosoda and K. Kangawa, Standard sample collections for blood ghrelin measurements, Methods Enzymol, vol.514, pp.113-126, 2012.

A. Howard, S. Feighner, D. Cully, J. Arena, P. Liberator et al., A receptor in pituitary and hypothalamus that functions in growth hormone release, vol.16, pp.974-977, 1996.

K. Hoyles and J. C. Sharma, Olfactory loss as a supporting feature in the diagnosis of Parkinson's disease: a pragmatic approach, J. Neurol, vol.260, pp.2951-2958, 2013.

S. Hwang, M. Moon, S. Kim, L. Hwang, K. J. Ahn et al., Neuroprotective effect of ghrelin is associated with decreased expression of prostate apoptosis response-4, Endocr. J, vol.56, pp.609-617, 2009.

P. Ibáñez, S. Lesage, S. Janin, E. Lohmann, F. Durif et al., Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms, Arch. Neurol, vol.66, pp.102-108, 2009.

A. Ieraci, A. Mallei, and M. Popoli, Social Isolation Stress Induces Anxious-Depressive-Like Behavior and Alterations of Neuroplasticity-Related Genes in Adult Male Mice, Neural Plast, p.6212983, 2016.

K. Ikemoto, I. Nagatsu, A. Nishimura, K. Nishi, and R. Arai, Do all of human midbrain tyrosine hydroxylase neurons synthesize dopamine?, Brain Res, vol.805, pp.255-258, 1998.

M. Iljina, G. A. Garcia, M. H. Horrocks, L. Tosatto, M. L. Choi et al., Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading, Proc. Natl. Acad. Sci. U. S. A, vol.113, pp.1206-1215, 2016.

A. Inui, Ghrelin: An orexigenic and somatotrophic signal from the stomach, Nat. Rev. Neurosci, vol.2, pp.551-560, 2001.

D. J. Irwin, V. M. Lee, .. Trojanowski, and J. Q. , Parkinson's disease dementia: convergence of ?synuclein, tau and amyloid-? pathologies, Nat. Rev. Neurosci, vol.14, pp.626-636, 2013.

V. Jackson-lewis, M. Jakowec, R. E. Burke, and S. Przedborski, Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurodegener. J. Neurodegener. Disord. Neuroprotection Neuroregeneration, vol.4, pp.257-269, 1995.

F. Jacob, Souris, la Mouche et l'Homme, 1996.

S. A. Jagmag, N. Tripathi, S. D. Shukla, S. Maiti, and S. Khurana, Evaluation of Models of Parkinson's Disease, Front. Neurosci, vol.9, 2016.

S. Jain, Y. Park, S. Comer, D. Rudoy, D. Ivanco et al., Identifying drug-naïve Parkinsonism with Non-motor features & CSF biomarkers: A case-control study, 2015.

W. Jang, H. J. Kim, H. Li, K. D. Jo, M. K. Lee et al., The Neuroprotective Effect of Erythropoietin on Rotenone-Induced Neurotoxicity in SH-SY5Y Cells Through the Induction of Autophagy, Mol. Neurobiol, vol.53, pp.3812-3821, 2015.

L. M. Jaremka, M. A. Belury, R. R. Andridge, W. B. Malarkey, R. Glaser et al., Interpersonal stressors predict ghrelin and leptin levels in women, Psychoneuroendocrinology, vol.48, pp.178-188, 2014.

H. Jiang, L. Betancourt, and R. G. Smith, Ghrelin Amplifies Dopamine Signaling by Cross Talk Involving Formation of Growth Hormone Secretagogue Receptor/Dopamine Receptor Subtype 1 Heterodimers, Mol. Endocrinol, vol.20, pp.1772-1785, 2006.

H. Jiang, L. Li, J. Wang, and J. Xie, Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra, Exp. Neurol, vol.212, pp.532-537, 2008.

I. P. Johnson, Age-related neurodegenerative disease research needs aging models. Front, Aging Neurosci, vol.7, p.168, 2015.

J. P. Johnston, Some observations upon a new inhibitor of monoamine oxidase in brain tissue, Biochem. Pharmacol, vol.17, pp.1285-1297, 1968.

T. M. Kääriäinen, M. Käenmäki, M. M. Forsberg, N. Oinas, A. Tammimäki et al., Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion, Basic Clin. Pharmacol. Toxicol, vol.110, pp.162-170, 2012.

G. Kadas, M. Klotz, K. Schäfer, K. Fassbender, D. Thomi et al., Do different assays for human acylated ghrelin concentrations provide comparable results?, Neuro Endocrinol. Lett, vol.35, pp.37-41, 2014.

M. E. Kalaitzakis, M. B. Graeber, S. M. Gentleman, and R. K. Pearce, Striatal beta-amyloid deposition in Parkinson disease with dementia, J. Neuropathol. Exp. Neurol, vol.67, pp.155-161, 2008.

L. V. Kalia, S. K. Kalia, P. J. Mclean, A. M. Lozano, and A. E. Lang, ?-Synuclein oligomers and clinical implications for Parkinson disease, Ann. Neurol, vol.73, pp.155-169, 2013.

L. V. Kalia and A. E. Lang, Parkinson's disease, Lancet Lond. Engl, vol.386, issue.14, pp.61393-61396, 2015.

K. Kalinderi, S. Bostantjopoulou, and L. Fidani, The genetic background of Parkinson's disease: current progress and future prospects, Acta Neurol. Scand, 2016.

J. Kamegai, I. Wakabayashi, R. D. Kineman, and L. A. Frohman, Growth hormone-releasing hormone receptor (GHRH-R) and growth hormone secretagogue receptor (GHS-R) mRNA levels during postnatal development in male and female rats, J. Neuroendocrinol, vol.11, pp.299-306, 1999.

J. Kang, D. J. Irwin, A. S. Chen-plotkin, A. Siderowf, C. Caspell et al., Association of cerebrospinal fluid ?-amyloid 1-42, T-tau, P-tau181, and ?-synuclein levels with clinical features of drug-naive patients with early Parkinson disease, JAMA Neurol, vol.70, pp.1277-1287, 2013.

H. Karasawa, C. Pietra, C. Giuliano, S. Garcia-rubio, X. Xu et al., New ghrelin agonist, HM01 alleviates constipation and L-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson's disease, Neurogastroenterol. Motil, 2014.

A. Karch, F. Llorens, M. Schmitz, A. S. Arora, S. Zafar et al., Stratification by Genetic and Demographic Characteristics Improves Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers in Rapidly Progressive Dementia, J. Alzheimers Dis. JAD, vol.54, pp.1385-1393, 2016.

S. Kay, M. Josefine, S. Siswanto, K. Reijko, H. Helmut et al., The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies, Brain Pathol. Zurich Switz, vol.25, pp.121-135, 2015.

P. C. Keane, M. Kurzawa, P. G. Blain, and C. M. Morris, Mitochondrial Dysfunction in Parkinson's Disease. Park. Dis, 2011.

R. Kenny, G. Cai, J. A. Bayliss, M. Clarke, Y. L. Choo et al., Endogenous ghrelin's role in hippocampal neuroprotection after global cerebral ischemia: does endogenous ghrelin protect against global stroke?, AJP Regul. Integr. Comp. Physiol, vol.304, 2013.

A. Kern, R. Albarran-zeckler, H. E. Walsh, and R. G. Smith, Apo-Ghrelin Receptor Forms Heteromers with DRD2 in Hypothalamic Neurons and Is Essential for Anorexigenic Effects of DRD2 Agonism, Neuron, vol.73, pp.317-332, 2012.

C. Kim, E. Rockenstein, B. Spencer, H. Kim, A. Adame et al., Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy, Cell Rep, vol.13, pp.771-782, 2015.

D. Kim, J. H. Paik, D. Shin, H. Kim, C. Park et al., What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?, Exp. Neurobiol, vol.23, pp.352-364, 2014.

G. J. Kim, S. Y. Park, H. Kim, Y. H. Chun, and S. H. Park, Chromosomal aberrations in neuroblastoma cell lines identified by cross species color banding and chromosome painting, Cancer Genet. Cytogenet, vol.129, pp.10-16, 2001.

J. Kim and H. Sung, Gastrointestinal Autonomic Dysfunction in Patients with Parkinson's Disease, J. Mov. Disord, vol.8, pp.76-82, 2015.

J. Kim and B. S. Jeon, Complementary and alternative medicine in Parkinson's disease patients in Korea, Curr. Neurol. Neurosci. Rep, vol.12, pp.631-632, 2012.

M. S. Kim, C. Y. Yoon, P. G. Jang, Y. J. Park, C. S. Shin et al., The mitogenic and antiapoptotic actions of ghrelin in 3T3-L1 adipocytes, Mol. Endocrinol. Baltim. Md, vol.18, pp.2291-2301, 2004.

R. H. Kim, P. D. Smith, H. Aleyasin, S. Hayley, M. P. Mount et al., Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress, Proc. Natl. Acad. Sci. U. S. A, vol.102, pp.5215-5220, 2005.

A. King, S. Maekawa, I. Bodi, C. Troakes, O. Curran et al., Simulated surgical-type cerebral biopsies from post-mortem brains allows accurate neuropathological diagnoses in the majority of neurodegenerative disease groups, Acta Neuropathol. Commun, vol.1, p.53, 2013.

D. Kirik, C. Rosenblad, C. Burger, C. Lundberg, T. E. Johansen et al., Parkinson-like neurodegeneration induced by targeted overexpression of ?-synuclein in the nigrostriatal system, J. Neurosci, vol.22, pp.2780-2791, 2002.

T. Kitada, S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura et al., Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature, vol.392, pp.605-608, 1998.

T. Kitada, A. Pisani, D. R. Porter, H. Yamaguchi, A. Tscherter et al., Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice, Proc. Natl. Acad. Sci. U. S. A, vol.104, pp.11441-11446, 2007.

D. J. Klionsky and S. D. Emr, Autophagy as a regulated pathway of cellular degradation, Science, vol.290, pp.1717-1721, 2000.

P. Klivenyi, D. Siwek, G. Gardian, L. Yang, A. Starkov et al., Mice lacking alpha-synuclein are resistant to mitochondrial toxins, Neurobiol. Dis, vol.21, pp.541-548, 2006.

T. P. Knowles, M. Vendruscolo, and C. M. Dobson, The amyloid state and its association with protein misfolding diseases, Nat. Rev. Mol. Cell Biol, vol.15, pp.384-396, 2014.

J. C. Koch, F. Bitow, J. Haack, Z. Hedouville, J. Zhang et al., Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons, Cell Death Dis, vol.6, p.1811, 2015.

S. Koga, N. Aoki, R. J. Uitti, J. A. Van-gerpen, W. P. Cheshire et al., When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients, Neurology, vol.85, pp.404-412, 2015.

J. Koikkalainen, H. Rhodius-meester, A. Tolonen, F. Barkhof, B. Tijms et al., Differential diagnosis of neurodegenerative diseases using structural MRI data, NeuroImage Clin, vol.11, pp.435-449, 2016.

M. Kojima, H. Hosoda, Y. Date, M. Nakazato, and H. Matsuo, Ghelin is a gowth-hormonereleasing acylated peptide from stomach, Nature, vol.402, pp.656-660, 1999.

M. Kojima and K. Kangawa, Ghrelin: structure and function, Physiol. Rev, vol.85, pp.495-522, 2005.

J. H. Kordower, Y. Chu, R. A. Hauser, T. B. Freeman, and C. W. Olanow, Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease, Nat. Med, vol.14, pp.504-506, 2008.

J. H. Kordower, T. B. Freeman, B. J. Snow, F. J. Vingerhoets, E. J. Mufson et al., Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease, N. Engl. J. Med, vol.332, pp.1118-1124, 1995.

J. A. Korecka, R. E. Van-kesteren, E. Blaas, S. O. Spitzer, J. H. Kamstra et al., Phenotypic Characterization of Retinoic Acid Differentiated SH-SY5Y Cells by Transcriptional Profiling, PLoS ONE, vol.8, 2013.

R. Kortekaas, K. L. Leenders, J. C. Van-oostrom, W. Vaalburg, J. Bart et al., Blood-brain barrier dysfunction in parkinsonian midbrain in vivo, Ann. Neurol, vol.57, pp.176-179, 2005.

P. T. Kotzbauer, N. J. Cairns, M. C. Campbell, A. W. Willis, B. A. Racette et al., Pathologic accumulation of ?-synuclein and A? in Parkinson disease patients with dementia, Arch. Neurol, vol.69, pp.1326-1331, 2012.

T. Kovács, N. J. Cairns, and P. L. Lantos, Olfactory centres in Alzheimer's disease: olfactory bulb is involved in early Braak's stages, Neuroreport, vol.12, pp.285-288, 2001.

P. Krack, A. Batir, N. Van-blercom, S. Chabardes, V. Fraix et al., Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease, N. Engl. J. Med, vol.349, pp.1925-1934, 2003.

S. M. Kranick and J. E. Duda, Olfactory dysfunction in Parkinson's disease, Neurosignals, vol.16, pp.35-40, 2008.

T. Lebouvier, M. Tasselli, S. Paillusson, H. Pouclet, M. Neunlist et al., Biopsable Neural Tissues: Toward New Biomarkers for Parkinson's Disease? Front, Psychiatry, vol.1, 2010.

C. S. Lee, H. Sauer, and A. Bjorklund, Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat, Neuroscience, vol.72, pp.641-653, 1996.

H. Lee, J. Suk, C. Patrick, E. Bae, J. Cho et al., Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies, J. Biol. Chem, vol.285, pp.9262-9272, 2010.

M. K. Lee, W. Stirling, Y. Xu, X. Xu, D. Qui et al., Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice, Proc. Natl. Acad. Sci. U. S. A, vol.99, pp.8968-8973, 2002.

A. F. Leentjens, K. Dujardin, L. Marsh, P. Martinez-martin, I. H. Richard et al., Anxiety rating scales in Parkinson's disease: Critique and recommendations, Mov. Disord, vol.23, 2008.

A. J. Lees, J. Hardy, T. Revesz, A. J. Lees, M. Selikhova et al., The black stuff and Konstantin Nikolaevich Tretiakoff, Mov. Disord. Off. J. Mov. Disord. Soc, vol.373, pp.777-783, 2008.

F. Lemarié, E. Beauchamp, P. Legrand, and V. Rioux, Revisiting the metabolism and physiological functions of caprylic acid (C8:0) with special focus on ghrelin octanoylation, Biochimie, vol.120, pp.40-48, 2016.

L. R. Lemkau, G. Comellas, K. D. Kloepper, W. S. Woods, J. M. George et al., Mutant protein A30P ?-synuclein adopts wild-type fibril structure, despite slower fibrillation kinetics, J. Biol. Chem, vol.287, pp.11526-11532, 2012.

L. R. Lemkau, G. Comellas, S. W. Lee, L. K. Rikardsen, W. S. Woods et al., Site-specific perturbations of alpha-synuclein fibril structure by the Parkinson's disease associated mutations A53T and E46K, PloS One, vol.8, p.49750, 2013.

E. Leroy, D. Anastasopoulos, S. Konitsiotis, C. Lavedan, and M. H. Polymeropoulos, Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease, Hum. Genet, vol.103, pp.424-427, 1998.

S. Lesage, M. Anheim, F. Letournel, L. Bousset, A. Honoré et al., French Parkinson's Disease Genetics Study Group, 2013. G51D ?-synuclein mutation causes a novel parkinsonian-pyramidal syndrome, Ann. Neurol, vol.73, pp.459-471

S. Lesage, V. Drouet, E. Majounie, V. Deramecourt, M. Jacoupy et al., Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy, Am. J. Hum. Genet, vol.98, pp.500-513, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01289266

S. Levi, M. Cox, M. Lugon, M. Hodkinson, and A. Tomkins, Increased energy expenditure in Parkinson's disease, BMJ, vol.301, pp.1256-1257, 1990.

F. Levin, T. Edholm, P. T. Schmidt, P. Grybäck, H. Jacobsson et al., Ghrelin Stimulates Gastric Emptying and Hunger in Normal-Weight Humans, J. Clin. Endocrinol. Metab, vol.91, pp.3296-3302, 2006.

J. Levin, A. Kurz, T. Arzberger, A. Giese, and G. U. Höglinger, The Differential Diagnosis and Treatment of Atypical Parkinsonism, Dtsch. Ärztebl. Int, vol.113, pp.61-69, 2016.

B. Levine and D. J. Klionsky, Development by self-digestion: molecular mechanisms and biological functions of autophagy, Dev. Cell, vol.6, pp.463-477, 2004.

P. A. Lewitt, Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics, Mov. Disord. Off. J. Mov. Disord. Soc, vol.30, pp.64-72, 2015.

F. Lewy, Paralysis agitans. I. Pathologische Anatomie, Handbuch der Neurologie. Lewandowski M, pp.920-933, 1912.

F. H. Lewy, Zur pathologisch-anatomischen Differentialdiagnose der Paralysis agitans und der Huntingtonschen Chorea, Z. Für Gesamte Neurol. Psychiatr, vol.73, pp.170-187, 1921.

F. Li, H. Ji, and L. Shen, A Meta-Analysis of Tea Drinking and Risk of Parkinson's, Disease. Sci. World J, 2012.

J. Li, E. Englund, H. Widner, S. Rehncrona, A. Björklund et al., Characterization of Lewy body pathology in 12-and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease, Mov. Disord. Off. J. Mov. Disord. Soc, vol.25, pp.1091-1096, 2010.

N. Li, Mitochondrial Complex I Inhibitor Rotenone Induces Apoptosis through Enhancing Mitochondrial Reactive Oxygen Species Production, J. Biol. Chem, vol.278, pp.8516-8525, 2003.

Y. Li, W. Liu, T. F. Oo, L. Wang, Y. Tang et al., Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease, Nat. Neurosci, vol.12, pp.826-828, 2009.

P. Limousin, P. Krack, P. Pollak, A. Benazzouz, C. Ardouin et al., Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease, N. Engl. J. Med, vol.339, pp.1105-1111, 1998.

P. Limousin, P. Pollak, A. Benazzouz, D. Hoffmann, E. Broussolle et al., Bilateral subthalamic nucleus stimulation for severe Parkinson's disease, Mov. Disord. Off. J. Mov. Disord. Soc, vol.10, pp.672-674, 1995.

C. Lin, J. Lin, Y. Liu, C. Chang, and R. Wu, Risk of Parkinson's disease following anxiety disorders: a nationwide population-based cohort study, Eur. J. Neurol, vol.22, pp.1280-1287, 2015.

O. Lindvall and A. Björklund, Cell therapy in Parkinson's disease, NeuroRx J. Am. Soc. Exp. Neurother, vol.1, pp.382-393, 2004.

L. Liu, J. Song, J. Lu, Y. Huang, Y. Zeng et al., Tianma Gouteng Yin, a Traditional Chinese Medicine decoction, exerts neuroprotective effects in animal and cellular models of Parkinson's disease, Sci. Rep, vol.5, p.16862, 2015.

Y. Liu, D. Peter, A. Roghani, S. Schuldiner, G. G. Privé et al., A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter, Cell, vol.70, pp.539-551, 1992.

K. J. Livak and T. D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods San Diego Calif, vol.25, pp.402-408, 2001.

F. Llorens, M. Schmitz, D. Varges, N. Kruse, N. Gotzmann et al., Cerebrospinal ?-synuclein in ?-synuclein aggregation disorders: tau/?-synuclein ratio as potential biomarker for dementia with Lewy bodies, J. Neurol, vol.263, pp.2271-2277, 2016.

C. Lo-bianco, J. Ridet, B. L. Schneider, N. Deglon, and P. Aebischer, alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease, Proc. Natl. Acad. Sci. U. S. A, vol.99, pp.10813-10818, 2002.

C. M. Long-smith, A. M. Sullivan, and Y. M. Nolan, The influence of microglia on the pathogenesis of Parkinson's disease, Prog. Neurobiol, vol.89, pp.277-287, 2009.

F. M. Lopes, R. Schröder, M. L. Júnior, F. Da, A. Zanotto-filho et al., Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies, Brain Res, vol.1337, pp.85-94, 2010.

N. Lorenzen, S. B. Nielsen, A. K. Buell, J. D. Kaspersen, P. Arosio et al., The role of stable ?-synuclein oligomers in the molecular events underlying amyloid formation, J. Am. Chem. Soc, vol.136, pp.3859-3868, 2014.

J. Lotharius, S. Barg, P. Wiekop, C. Lundberg, H. K. Raymon et al., Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line, J. Biol. Chem, vol.277, pp.38884-38894, 2002.

X. Lu, S. M. Fleming, B. Meurers, L. C. Ackerson, F. Mortazavi et al., Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein, J. Neurosci. Off. J. Soc. Neurosci, vol.29, pp.1962-1976, 2009.

P. Luoma, A. Melberg, J. O. Rinne, J. A. Kaukonen, N. N. Nupponen et al., Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study, Lancet Lond. Engl, vol.364, pp.16983-16986, 2004.

E. S. Luth, I. G. Stavrovskaya, T. Bartels, B. S. Kristal, and D. J. Selkoe, Soluble, Prefibrillar ?-Synuclein Oligomers Promote Complex I-dependent, Ca2+-induced Mitochondrial Dysfunction, J. Biol. Chem, vol.289, pp.21490-21507, 2014.

J. Luthman, A. Fredriksson, E. Sundström, G. Jonsson, and T. Archer, Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage, Behav. Brain Res, vol.33, pp.267-277, 1989.

I. Mackenzie, The pathology of Parkinson's disease. Br. Columbia Med, J, vol.43, pp.142-147, 2001.

J. Makovey, V. Naganathan, M. Seibel, and P. Sambrook, Gender differences in plasma ghrelin and its relations to body composition and bone -an opposite-sex twin study, Clin. Endocrinol. (Oxf.), vol.66, pp.530-537, 2007.

B. K. Mani, A. K. Walker, E. J. Lopez-soto, J. Raingo, C. E. Lee et al., Neuroanatomical characterization of a growth hormone secretagogue receptorgreen fluorescent protein reporter mouse: Characterization of Ghsr-egfp reporter mouse, J. Comp. Neurol, vol.522, pp.3644-3666, 2014.

A. B. Manning-bo?, W. M. Caudle, X. A. Perez, S. H. Reaney, R. Paletzki et al., Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter, Neurobiol. Dis, vol.27, pp.141-150, 2007.

A. B. Manning-bog, A. L. Mccormack, J. Li, V. N. Uversky, A. L. Fink et al., The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein, J. Biol. Chem, vol.277, pp.1641-1644, 2002.

K. Marder, M. Tang, H. Mejia, B. Alfaro, L. Cote et al., Risk of Parkinson's disease among first-degree relatives A community-based study, Neurology, vol.47, pp.155-160, 1996.

C. Marin and E. Aguilar, In vivo 6-OHDA-induced neurodegeneration and nigral autophagic markers expression, Neurochem. Int, vol.58, pp.521-526, 2011.

E. Markaki, J. Ellul, Z. Kefalopoulou, E. Trachani, A. Theodoropoulou et al., The Role of Ghrelin, Neuropeptide Y and Leptin Peptides in Weight Gain after Deep Brain Stimulation for Parkinson's Disease, Stereotact. Funct. Neurosurg, vol.90, pp.104-112, 2012.

H. S. Markus, M. Cox, and A. M. Tomkins, Raised resting energy expenditure in Parkinson's disease and its relationship to muscle rigidity, Clin. Sci, vol.83, pp.199-204, 1992.

M. Martinez-vicente, Autophagy in neurodegenerative diseases: From pathogenic dysfunction to therapeutic modulation, Semin. Cell Dev. Biol, vol.40, pp.115-126, 2015.

M. Martinez-vicente and A. M. Cuervo, Autophagy and neurodegeneration: when the cleaning crew goes on strike, Lancet Neurol, vol.6, pp.352-361, 2007.

L. Martins, D. Fernández-mallo, M. G. Novelle, M. J. Vázquez, M. Tena-sempere et al., Hypothalamic mTOR Signaling Mediates the Orexigenic Action of Ghrelin, PLoS ONE, vol.7, 2012.

S. Mary, J. Fehrentz, M. Damian, G. Gaibelet, H. Orcel et al., Heterodimerization with Its Splice Variant Blocks the Ghrelin Receptor 1a in a Non-signaling Conformation, J. Biol. Chem, vol.288, pp.24656-24665, 2013.

E. Masliah, E. Rockenstein, M. Mante, L. Crews, B. Spencer et al., Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease, PloS One, vol.6, 2011.

E. Masliah, E. Rockenstein, I. Veinbergs, M. Mallory, M. Hashimoto et al., Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders, Science, vol.287, pp.1265-1269, 2000.

N. Maswood, J. Young, E. Tilmont, Z. Zhang, D. M. Gash et al., Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease, Proc. Natl. Acad. Sci. U. S. A, vol.101, pp.18171-18176, 2004.

H. Matsumine, A Parkin gene (PARK 2) and Parkinson's disease, 1999.

, Rinsh? Shinkeigaku Clin. Neurol, vol.39, pp.9-12

H. Matsumine, M. Saito, S. Shimoda-matsubayashi, H. Tanaka, A. Ishikawa et al., Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27, Am. J. Hum. Genet, vol.60, pp.588-596, 1997.

R. Mayeux, J. Denaro, N. Hemenegildo, K. Marder, M. X. Tang et al., A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender, Arch. Neurol, vol.49, pp.492-497, 1992.

R. W. Mccallum, A. Lembo, T. Esfandyari, B. R. Bhandari, N. Ejskjaer et al., Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis, Neurogastroenterol. Motil, vol.25, pp.705-717, 2013.

A. L. Mccormack and D. A. Di-monte, Effects of L-dopa and other amino acids against paraquatinduced nigrostriatal degeneration, J. Neurochem, vol.85, pp.82-86, 2003.

W. T. Mckinney, Animal models of depression: an overview, Psychiatr. Dev, vol.2, pp.77-96, 1984.

D. A. Mcritchie, H. R. Cartwright, and G. M. Halliday, Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease, Exp. Neurol, vol.144, pp.202-213, 1997.

Y. Mear, A. Enjalbert, and S. Thirion, GHS-R1a constitutive activity and its physiological relevance, Front. Neurosci, vol.7, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00966209

M. Méquinion, E. Caron, S. Zgheib, A. Stievenard, P. Zizzari et al., Physical activity: benefit or weakness in metabolic adaptations in a mouse model of chronic food restriction?, Am. J. Physiol. -Endocrinol, 2015.

. Metab, , vol.308, pp.241-255

M. Méquinion, F. Langlet, S. Zgheib, S. Dickson, B. Dehouck et al., Ghrelin: Central and Peripheral Implications in Anorexia Nervosa, 2013.

G. E. Meredith, S. Totterdell, E. Petroske, K. Santa-cruz, R. C. Callison et al., Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease, Brain Res, vol.956, pp.156-165, 2002.

M. Meulener, A. J. Whitworth, C. E. Armstrong-gold, P. Rizzu, P. Heutink et al., Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease, Curr. Biol. CB, vol.15, pp.1572-1577, 2005.

E. Mezey, A. M. Dehejia, G. Harta, N. Tresser, S. F. Suchy et al., Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease, Mol. Psychiatry, vol.3, pp.493-499, 1998.

M. Mogi, M. Harada, H. Narabayashi, H. Inagaki, M. Minami et al., Interleukin (IL)-1?, IL-2, IL-4, IL-6 and transforming growth factor-? levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease, Neurosci. Lett, vol.211, pp.13-16, 1996.

A. Molfino, A. Formiconi, F. R. Fanelli, and M. Muscaritoli, Ghrelin: from discovery to cancer cachexia therapy, Curr. Opin. Clin. Nutr. Metab. Care, vol.17, pp.471-476, 2014.

C. Moolenbeek and E. J. Ruitenberg, The "Swiss roll": a simple technique for histological studies of the rodent intestine, Lab. Anim, vol.15, pp.57-59, 1981.

M. Moon, H. G. Kim, L. Hwang, J. Seo, S. Kim et al., Neuroprotective Effect of Ghrelin in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson's Disease by Blocking Microglial Activation, Neurotox. Res, vol.15, pp.332-347, 2009.

J. F. Morley and J. E. Duda, Olfaction as a biomarker in Parkinson's disease, Biomark. Med, vol.4, pp.661-670, 2010.

P. Morrish, The meaning of negative DAT SPECT and F-Dopa PET scans in patients with clinical Parkinson's disease, Mov. Disord. Off. J. Mov. Disord. Soc, vol.20, 0117.

A. Mougenot, S. Nicot, A. Bencsik, E. Morignat, J. Verchère et al., Prion-like acceleration of a synucleinopathy in a transgenic mouse model, Neurobiol. Aging, vol.33, pp.2225-2228, 2012.

A. J. Mougenot, A. Bencsik, S. Nicot, J. Vulin, E. Morignat et al., Transmission of prion strains in a transgenic mouse model overexpressing human A53T mutated ?-synuclein, J. Neuropathol. Exp. Neurol, vol.70, pp.377-385, 2011.

, The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations, Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease, vol.18, pp.738-750, 2003.

T. D. Müller, R. Nogueiras, M. L. Andermann, Z. B. Andrews, S. D. Anker et al., Ghrelin. Mol. Metab, vol.4, pp.437-460, 2015.

E. Muñoz, R. Oliva, V. Obach, M. J. Martí, P. Pastor et al., Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the alphasynuclein gene in early onset patients, Neurosci. Lett, vol.235, pp.57-60, 1997.

A. B. Muñoz-manchado, J. Villadiego, S. Romo-madero, N. Suárez-luna, A. Bermejo-navas et al., Chronic and progressive Parkinson's disease MPTP model in adult and aged mice, J. Neurochem, vol.136, pp.373-387, 2016.

J. Munro, K. Steeghs, V. Morrison, H. Ireland, and K. Parkinsn, Human fibroblast replicative senescence can occur in the absence of extensive cell division and short telomeres, Publ. Online, vol.14, 2001.

E. Mutez, L. Larvor, F. Leprêtre, V. Mouroux, D. Hamalek et al., Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation, Neurobiol. Aging, vol.32, pp.1839-1848, 2011.

E. Mutez, A. Nkiliza, K. Belarbi, A. De-broucker, C. Vanbesien-mailliot et al., Involvement of the immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson's disease, Neurobiol. Dis, vol.63, pp.165-170, 2014.

T. Nagatsu, M. Mogi, H. Ichinose, and A. Togari, Cytokines in Parkinson's disease, J. Neural Transm, pp.143-151, 2000.

K. Nakamura, V. P. Bindokas, J. D. Marks, D. A. Wright, D. M. Frim et al., The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited, Mol. Pharmacol, vol.58, pp.271-278, 2000.

M. A. Nalls, N. Pankratz, C. M. Lill, C. B. Do, D. G. Hernandez et al., International Parkinson's Disease Genomics Consortium (ipdgc), Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (progeni), 23andMe, GenePD, NeuroGenetics Research Consortium (ngrc), Hussman Institute of Human Genomics (hihg), vol.46, pp.989-993, 2014.

D. Narendra, A. Tanaka, D. Suen, and R. J. Youle, Parkin is recruited selectively to impaired mitochondria and promotes their autophagy, J. Cell Biol, vol.183, pp.795-803, 2008.

, What are the Different Types of Atypical Parkinsonism Syndromes? | National Parkinson Foundation

A. Navarro and A. Boveris, Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson's disease. Front, Aging Neurosci, vol.2, 2010.

C. Ng, S. Z. Mok, C. Koh, X. Ouyang, M. L. Fivaz et al., Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila, J. Neurosci. Off. J. Soc. Neurosci, vol.29, pp.11257-11262, 2009.

K. Y. Ng, T. N. Chase, R. W. Colburn, and I. J. Kopin, L-Dopa-induced release of cerebral monoamines, Science, vol.170, pp.76-77, 1970.

K. Y. Ng, R. W. Colburn, and I. J. Kopin, Effects of L-dopa on efflux of cerebral monoamines from synaptosomes, Nature, vol.230, pp.331-332, 1971.

Y. Nishi, H. Mifune, A. Yabuki, Y. Tajiri, R. Hirata et al., Changes in Subcellular Distribution of n-Octanoyl or n-Decanoyl Ghrelin in Ghrelin-Producing Cells, 2013.

A. J. Noyce, A. J. Lees, and A. Schrag, The prediagnostic phase of Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, 2016.

S. Nozaki, T. Saito, T. Matsumura, I. Miyai, and J. Kang, , 1999.

, Rinsho Shinkeigaku, vol.39, pp.1010-1014

R. L. Nussbaum and M. H. Polymeropoulos, Genetics of Parkinson's disease, Hum. Mol. Genet, vol.6, pp.1687-1691, 1997.

S. Nuvoli, A. Spanu, and G. Madeddu, Brain SPECT with perfusion radiopharmaceuticals and dopaminergic system radiocompounds in dementia disorders, Curr. Alzheimer Res, 2016.

J. A. Obeso, M. C. Rodríguez, A. Gorospe, J. Guridi, L. Alvarez et al., Surgical treatment of Parkinson's disease, Baillières Clin. Neurol, vol.6, pp.125-145, 1997.

W. Oertel and J. B. Schulz, Current and experimental treatments of Parkinson disease: A guide for neuroscientists, J. Neurochem, 2016.

N. U. Okubadejo, J. H. Bower, W. A. Rocca, and D. M. Maraganore, Parkinson's disease in Africa: A systematic review of epidemiologic and genetic studies, Mov. Disord. Off. J. Mov. Disord. Soc, vol.21, pp.2150-2156, 2006.

C. W. Olanow and K. S. Mcnaught, Ubiquitin-proteasome system and Parkinson's disease, Mov. Disord. Off. J. Mov. Disord. Soc, vol.21, pp.1806-1823, 2006.

C. W. Olanow and S. B. Prusiner, Is Parkinson's disease a prion disorder?, Proc. Natl. Acad. Sci. U. S. A, vol.106, pp.12571-12572, 2009.

J. Olesen and M. Leonardi, The burden of brain diseases in Europe, Eur. J. Neurol, vol.10, pp.471-477, 2003.

S. Olgiati, A. De-rosa, M. Quadri, C. Criscuolo, G. J. Breedveld et al., PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family, Neurogenetics, vol.15, pp.183-188, 2014.

P. K. Olszewski, H. B. Schiöth, and A. S. Levine, Ghrelin in the CNS: from hunger to a rewarding and memorable meal?, Brain Res. Rev, vol.58, pp.160-170, 2008.

L. Oreland, Monoamine oxidase, dopamine and Parkinson's disease, Acta Neurol. Scand. Suppl, vol.136, pp.60-65, 1991.

C. F. Orr, D. B. Rowe, and G. M. Halliday, An inflammatory review of Parkinson's disease, Prog. Neurobiol, vol.68, pp.325-340, 2002.

A. Oueslati, K. E. Paleologou, B. L. Schneider, P. Aebischer, and H. A. Lashuel, Mimicking phosphorylation at serine 87 inhibits the aggregation of human ?-synuclein and protects against its toxicity in a rat model of Parkinson's disease, J. Neurosci. Off. J. Soc. Neurosci, vol.32, pp.1536-1544, 2012.

A. Özge, R. Bugdayci, E. Togrol, and M. Saracoglu, The relation of gastrointestinal symptoms to duration of loveo-dopa treatment and severity of Parkinson's disease, J. Appl. Res, vol.3, pp.349-355, 2003.

E. Özta? and T. Topal, A Cell Protective Mechanism in a Murine Model of Parkinson's Disease. Turk, J. Med. Sci, vol.33, pp.295-299, 2003.

F. Pagan, M. Hebron, E. H. Valadez, Y. Torres-yaghi, X. Huang et al., Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies, J. Park. Dis, vol.6, pp.503-517, 2016.

T. Pan, S. Kondo, W. Le, and J. Jankovic, The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease, Brain J. Neurol, vol.131, 1969.

C. Pañeda, A. I. Arroba, L. M. Frago, A. M. Holm, J. Rømer et al., Growth hormone-releasing peptide-6 inhibits cerebellar cell death in aged rats, Neuroreport, vol.14, pp.1633-1635, 2003.

N. Pankratz, W. C. Nichols, S. K. Uniacke, C. Halter, J. Murrell et al., Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families, Hum. Mol. Genet, vol.12, pp.2599-2608, 2003.

N. Pankratz, J. B. Wilk, J. C. Latourelle, A. L. Destefano, C. Halter et al., Genomewide association study for susceptibility genes contributing to familial Parkinson disease, Hum. Genet, vol.124, pp.593-605, 2009.

F. Pan-montojo, O. Anichtchik, Y. Dening, L. Knels, S. Pursche et al., Progression of Parkinson's Disease Pathology Is Reproduced by Intragastric Administration of Rotenone in Mice, PLoS ONE, vol.5, 2010.

F. Pan-montojo, M. Schwarz, C. Winkler, M. Arnhold, G. A. O'sullivan et al., Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice, Sci. Rep, vol.2, 2012.

J. Pantel, M. Legendre, S. Cabrol, L. Hilal, Y. Hajaji et al., Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature, J. Clin. Invest, vol.116, pp.760-768, 2006.
URL : https://hal.archives-ouvertes.fr/hal-02082146

S. Papapetropoulos, C. Paschalis, A. Athanassiadou, A. Papadimitriou, J. Ellul et al., Clinical phenotype in patients with ?-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, vol.70, pp.662-665, 2001.

T. D. Papkovskaia, K. Chau, F. Inesta-vaquera, D. B. Papkovsky, D. G. Healy et al., G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization, Hum. Mol. Genet, vol.21, pp.4201-4213, 2012.

J. Park, S. Y. Kim, G. Cha, S. B. Lee, S. Kim et al., Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction, Gene, vol.361, pp.133-139, 2005.

J. Park, S. B. Lee, S. Lee, Y. Kim, S. Song et al., Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin, Nature, vol.441, pp.1157-1161, 2006.

J. Parkinson, An essay on the shaking palsy, J. Neuropsychiatry Clin. Neurosci, vol.14, pp.223-236, 2002.

, Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group, JAMA, vol.284, pp.1931-1938, 2000.

L. Pasquali, S. Ruggieri, L. Murri, A. Paparelli, and F. Fornai, Does autophagy worsen or improve the survival of dopaminergic neurons?, Parkinsonism Relat. Disord, vol.15, pp.24-27, 2009.

W. Peelaerts, L. Bousset, A. Van-der-perren, A. Moskalyuk, R. Pulizzi et al., ?-Synuclein strains cause distinct synucleinopathies after local and systemic administration, Nature, vol.522, pp.340-344, 2015.

F. A. Perez and R. D. Palmiter, Parkin-deficient mice are not a robust model of parkinsonism, Proc. Natl. Acad. Sci. U. S. A, vol.102, pp.2174-2179, 2005.

C. Perier and M. Vila, Mitochondrial biology and Parkinson's disease. Cold Spring Harb, Perspect. Med, vol.2, p.9332, 2012.

M. Periquet, T. Fulga, L. Myllykangas, M. G. Schlossmacher, and M. B. Feany, Aggregated alphasynuclein mediates dopaminergic neurotoxicity in vivo, J. Neurosci. Off. J. Soc. Neurosci, vol.27, pp.3338-3346, 2007.

C. Perlemoine, F. Macia, F. Tison, I. Coman, D. Guehl et al., Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in Parkinson's disease, Br. J. Nutr, vol.93, pp.191-198, 2005.

S. Perrin, Preclinical research: Make mouse studies work, Nature, vol.507, pp.423-425, 2014.

Y. Pesah, T. Pham, H. Burgess, B. Middlebrooks, P. Verstreken et al., Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress, Dev. Camb. Engl, vol.131, pp.2183-2194, 2004.

G. M. Petzinger and M. W. Jakowec, Animal models of basal ganglia injury and degeneration and their application to Parkinson's disease research, 2005.

R. Pfeiffer, . Zbigniew-wszolek, and M. Ebadi, Parkinson's Disease, Second Edition, second, 2012.

R. F. Pfeiffer, Gastrointestinal dysfunction in Parkinson's disease, Parkinsonism Relat. Disord, vol.17, pp.10-15, 2011.

P. Piccini, D. J. Burn, R. Ceravolo, D. Maraganore, and D. J. Brooks, The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins, Ann. Neurol, vol.45, pp.577-582, 1999.

A. R. Pikstra, A. Van-der-hoorn, K. L. Leenders, and B. M. De-jong, Relation of 18-F-Dopa PET with hypokinesia-rigidity, tremor and freezing in Parkinson's disease, NeuroImage Clin, vol.11, pp.68-72, 2016.

A. Poehler, W. Xiang, P. Spitzer, V. E. May, H. Meixner et al., Autophagy modulates SNCA/?-synuclein release, thereby generating a hostile microenvironment, Autophagy, vol.10, pp.2171-2192, 2014.

W. Poewe, Non-motor symptoms in Parkinson's disease, Eur. J. Neurol, vol.15, pp.14-20, 2008.

W. Poewe, F. Gerstenbrand, G. Ransmayr, and S. Plörer, Premorbid personality of Parkinson patients, J. Neural Transm. Suppl, vol.19, pp.215-224, 1983.

M. Poletti, G. Perugi, C. Logi, A. Romano, P. Del-dotto et al., Dopamine agonists and delusional jealousy in Parkinson's disease: A cross-sectional prevalence study, Mov. Disord, vol.27, pp.1679-1682, 2012.

P. Pollak, A. L. Benabid, C. Gross, D. M. Gao, A. Laurent et al., , 1993.

, Rev. Neurol, vol.149, pp.175-176

M. H. Polymeropoulos, Autosomal dominant Parkinson's disease and alpha-synuclein, Ann. Neurol, vol.44, pp.63-64, 1998.

M. H. Polymeropoulos, J. J. Higgins, L. I. Golbe, W. G. Johnson, S. E. Ide et al., Mapping of a gene for Parkinson's disease to chromosome 4q21-q23, Science, vol.274, pp.1197-1199, 1996.

M. M. Ponsen, D. Stoffers, J. Booij, B. L. Van-eck-smit, E. C. Wolters et al., Idiopathic hyposmia as a preclinical sign of Parkinson's disease, Ann. Neurol, vol.56, pp.173-181, 2004.

R. Porcari, C. Proukakis, C. A. Waudby, B. Bolognesi, P. P. Mangione et al., The H50Q mutation induces a 10-fold decrease in the solubility of ?-synuclein, J. Biol. Chem, vol.290, pp.2395-2404, 2015.

P. E. Porporato, N. Filigheddu, S. Reano, M. Ferrara, E. Angelino et al., Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice, J. Clin. Invest, vol.123, pp.611-622, 2013.

R. B. Postuma, D. Berg, M. Stern, W. Poewe, C. W. Olanow et al., MDS clinical diagnostic criteria for Parkinson's disease, Mov. Disord, vol.30, pp.1591-1601, 2015.

K. Prasad, E. Tarasewicz, J. Mathew, P. A. Strickland, B. Buckley et al., Toxicokinetics and toxicodynamics of paraquat accumulation in mouse brain, Exp. Neurol, vol.215, pp.358-367, 2009.

R. D. Prediger, L. C. Batista, R. Medeiros, P. Pandolfo, J. C. Florio et al., The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease, Exp. Neurol, vol.202, pp.391-403, 2006.

R. D. Prediger, D. Rial, R. Medeiros, C. P. Figueiredo, R. L. Doty et al., Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease, Ann. N. Y. Acad. Sci, vol.1170, pp.629-636, 2009.

T. Pringsheim, N. Jette, A. Frolkis, and T. D. Steeves, The prevalence of Parkinson's disease: a systematic review and meta-analysis, Mov. Disord. Off. J. Mov. Disord. Soc, vol.29, pp.1583-1590, 2014.

C. C. Probst and T. Van-eimeren, The Functional Anatomy of Impulse Control Disorders, Curr. Neurol. Neurosci. Rep, vol.13, 2013.

J. Pruszak, L. Just, O. Isacson, and G. Nikkhah, Isolation and culture of ventral mesencephalic precursor cells and dopaminergic neurons from rodent brains, Curr. Protoc. Stem Cell Biol. Chapter, 2009.

S. Przedborski, M. Levivier, H. Jiang, M. Ferreira, V. Jackson-lewis et al., Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine, Neuroscience, vol.67, pp.631-647, 1995.

M. Quaak, C. P. Van-schayck, A. M. Knaapen, and F. J. Van-schooten, Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases?, Eur. Respir. J, vol.33, pp.468-480, 2009.

K. Radad, G. Gille, and W. Rausch, Dopaminergic neurons are preferentially sensitive to longterm rotenone toxicity in primary cell culture, Toxicol. In Vitro, vol.22, pp.68-74, 2008.

K. Radad, R. Moldzio, M. Taha, and W. Rausch, Thymoquinone protects dopaminergic neurons against MPP + and rotenone, Phytother. Res, vol.23, pp.696-700, 2009.

D. Rail, C. Scholtz, and M. Swash, Post-encephalitic Parkinsonism: current experience, J. Neurol. Neurosurg. Psychiatry, vol.44, pp.670-676, 1981.

P. R. Rajendran, R. E. Thompson, and S. G. Reich, The use of alternative therapies by patients with Parkinson's disease, Neurology, vol.57, pp.790-794, 2001.

C. Ramaker, J. Marinus, A. M. Stiggelbout, and B. J. Van-hilten, Systematic evaluation of rating scales for impairment and disability in Parkinson's disease, Mov. Disord. Off. J. Mov. Disord. Soc, vol.17, pp.867-876, 2002.

D. Ramonet, J. P. Daher, B. M. Lin, K. Stafa, J. Kim et al., Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2, PloS One, vol.6, p.18568, 2011.

S. Reano, A. Graziani, and N. Filigheddu, Acylated and unacylated ghrelin administration to blunt muscle wasting, Curr. Opin. Clin. Nutr. Metab. Care, vol.17, pp.236-240, 2014.

A. Rediger, C. L. Piechowski, K. Habegger, A. Grüters, H. Krude et al., MC4R Dimerization in the Paraventricular Nucleus and GHSR/MC3R Heterodimerization in the Arcuate Nucleus: Is There Relevance for Body Weight Regulation, Neuroendocrinology, vol.95, pp.277-288, 2012.

N. L. Rey, S. George, and P. Brundin, Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein, 2016.

, Neuropathol. Appl. Neurobiol, vol.42, pp.51-76

J. R. Richardson, Y. Quan, T. B. Sherer, J. T. Greenamyre, and G. W. Miller, Paraquat neurotoxicity is distinct from that of MPTP and rotenone, Toxicol. Sci. Off. J. Soc. Toxicol, vol.88, pp.193-201, 2005.

P. Riederer and S. Wuketich, Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis, J. Neural Transm, vol.38, pp.277-301, 1976.

A. E. Rigamonti, A. I. Pincelli, B. Corrà, R. Viarengo, S. M. Bonomo et al., Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients, J. Endocrinol, vol.175, pp.1-5, 2002.

A. Rodríguez, J. Gómez-ambrosi, V. Catalán, M. J. Gil, S. Becerril et al., Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes, Int. J. Obes, vol.33, pp.541-552, 2005.

G. Rosati, E. Granieri, L. Pinna, I. Aiello, R. Tola et al., The risk of Parkinson disease in Mediterranean people, Neurology, vol.30, pp.250-255, 1980.

C. A. Ross and M. A. Poirier, Opinion: What is the role of protein aggregation in neurodegeneration?, Nat. Rev. Mol. Cell Biol, vol.6, pp.891-898, 2005.

G. W. Ross and H. Petrovitch, Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease, Drugs Aging, vol.18, pp.797-806, 2001.

G. W. Ross, H. Petrovitch, R. D. Abbott, C. M. Tanner, J. Popper et al., Association of olfactory dysfunction with risk for future Parkinson's disease, Ann. Neurol, vol.63, pp.167-173, 2008.

Z. L. Rossetti, A. Sotgiu, D. E. Sharp, M. Hadjiconstantinou, and N. H. Neff, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro, Biochem. Pharmacol, vol.37, pp.4573-4574, 1988.

C. Rossi, D. Frosini, D. Volterrani, P. De-feo, E. Unti et al., Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study, Eur. J. Neurol, vol.17, pp.626-630, 2010.

M. W. Rousseaux, P. C. Marcogliese, D. Qu, S. J. Hewitt, S. Seang et al., Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease, Proc. Natl. Acad. Sci. U. S. A, vol.109, pp.15918-15923, 2012.

J. M. Ruijter, C. Ramakers, W. M. Hoogaars, Y. Karlen, O. Bakker et al., Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data, Nucleic Acids Res, vol.37, 2009.

B. J. Ryan, L. L. Lourenço-venda, M. J. Crabtree, A. B. Hale, K. M. Channon et al., ?-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease. Free Radic, Biol. Med, vol.67, pp.58-68, 2014.

K. Sääksjärvi, P. Knekt, H. Rissanen, M. A. Laaksonen, A. Reunanen et al., Prospective study of coffee consumption and risk of Parkinson's disease, Eur. J. Clin. Nutr, vol.62, pp.908-915, 2008.

K. Saigoh, Y. L. Wang, J. G. Suh, T. Yamanishi, Y. Sakai et al., Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice, Nat. Genet, vol.23, pp.47-51, 1999.

A. Sakaguchi-nakashima, J. Y. Meir, Y. Jin, K. Matsumoto, and N. Hisamoto, LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins, Curr. Biol. CB, vol.17, pp.592-598, 2007.

J. Sämann, J. Hegermann, E. Von-gromoff, S. Eimer, R. Baumeister et al., Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth, J. Biol. Chem, vol.284, pp.16482-16491, 2009.

J. R. Santos, J. A. Cunha, A. L. Dierschnabel, C. L. Campêlo, A. H. Leão et al., Cognitive, motor and tyrosine hydroxylase temporal impairment in a model of parkinsonism induced by reserpine, Behav. Brain Res, vol.253, pp.68-77, 2013.

W. Satake, Y. Nakabayashi, I. Mizuta, Y. Hirota, C. Ito et al., Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease, Nat. Genet, vol.41, pp.1303-1307, 2009.

M. Satou, Y. Nishi, J. Yoh, Y. Hattori, and H. Sugimoto, Identification and characterization of acylprotein thioesterase 1/lysophospholipase I as a ghrelin deacylation/lysophospholipid hydrolyzing enzyme in fetal bovine serum and conditioned medium, Endocrinology, vol.151, pp.4765-4775, 2010.

M. Sawada, K. Imamura, and T. Nagatsu, Role of cytokines in inflammatory process in Parkinson's disease, J. Neural Transm, pp.373-381, 2006.

G. V. Sawle, S. J. Wroe, A. J. Lees, D. J. Brooks, and R. S. Frackowiak, The identification of presymptomatic parkinsonism: clinical and [18F]dopa positron emission tomography studies in an Irish kindred, Ann. Neurol, vol.32, pp.609-617, 1992.

M. Schaeffer, F. Langlet, C. Lafont, F. Molino, D. J. Hodson et al., Rapid sensing of circulating ghrelin by hypothalamic appetite-modifying neurons, Proc. Natl. Acad. Sci. U. S. A, vol.110, pp.1512-1517, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00796900

T. Schallert, S. M. Fleming, J. L. Leasure, J. L. Tillerson, and S. T. Bland, CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury, neuropharmacology, vol.39, pp.777-787, 2000.

A. Schanze, U. Reulbach, M. Scheuchenzuber, M. Groschl, J. Kornhuber et al., Ghrelin and eating disturbances in psychiatric disorders, Neuropsychobiology, vol.57, pp.126-130, 2008.

A. H. Schapira, Recent developments in biomarkers in Parkinson disease, Curr. Opin. Neurol, vol.26, pp.395-400, 2013.

A. H. Schapira, Neurobiology and treatment of Parkinson's disease, Trends Pharmacol. Sci, vol.30, pp.41-47, 2009.

A. H. Schapira, M. Emre, P. Jenner, and W. Poewe, Levodopa in the treatment of Parkinson's disease, Eur. J. Neurol, vol.16, pp.982-989, 2009.

H. Schellekens, T. G. Dinan, and J. F. Cryan, Taking two to tango: a role for ghrelin receptor heterodimerization in stress and reward, Front. Neurosci, vol.7, 2013.

C. H. Schenck, S. R. Bundlie, and M. W. Mahowald, Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder, Neurology, vol.46, pp.388-393, 1996.

M. G. Schlossmacher, M. P. Frosch, W. P. Gai, M. Medina, N. Sharma et al., Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies, Am. J. Pathol, vol.160, issue.10, pp.61113-61116, 2002.

B. S. Schoenberg, B. O. Osuntokun, A. O. Adeuja, O. Bademosi, V. Nottidge et al., Comparison of the prevalence of Parkinson's disease in black populations in the rural United States and in rural Nigeria: door-to-door community studies, Neurology, vol.38, pp.645-646, 1988.

B. Schüle, R. A. Pera, and J. W. Langston, Can cellular models revolutionize drug discovery in Parkinson's disease?, Biochim. Biophys. Acta BBA -Mol. Basis Dis, vol.1792, pp.1043-1051, 2009.

F. Schuler and J. E. Casida, The insecticide target in the PSST subunit of complex I, Pest Manag. Sci, vol.57, pp.932-940, 2001.

M. Sedelis, K. Hofele, G. W. Auburger, S. Morgan, J. P. Huston et al., MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences, Behav. Genet, vol.30, pp.171-182, 2000.

P. Seibler, J. Graziotto, H. Jeong, F. Simunovic, C. Klein et al., Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 iPS cells, J. Neurosci. Off. J. Soc. Neurosci, vol.31, pp.5970-5976, 2011.

I. Seim, S. L. Carter, A. C. Herington, and L. K. Chopin, Complex organisation and structure of the ghrelin antisense strand gene GHRLOS, a candidate non-coding RNA gene, BMC Mol. Biol, vol.9, p.95, 2008.

I. Seim, S. L. Carter, A. C. Herington, and L. K. Chopin, Complex organisation and structure of the ghrelin antisense strand gene GHRLOS, a candidate non-coding RNA gene, BMC Mol. Biol, vol.9, p.95, 2008.

I. Seim, C. Collet, A. C. Herington, and L. K. Chopin, Revised genomic structure of the human ghrelin gene and identification of novel exons, alternative splice variants and natural antisense transcripts, BMC Genomics, vol.8, p.298, 2007.

M. Selikhova, D. R. Williams, P. A. Kempster, J. L. Holton, T. Revesz et al., A clinicopathological study of subtypes in Parkinson's disease, Brain J. Neurol, vol.132, pp.2947-2957, 2009.

T. J. Shafer and W. D. Atchison, Transmitter, ion channel and receptor properties of pheochromocytoma (PC12) cells: a model for neurotoxicological studies, Neurotoxicology, vol.12, pp.473-492, 1991.

P. Shahim, K. Blennow, P. Johansson, J. Svensson, S. Lista et al., Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders, Neuromolecular Med, 2016.

S. Sharma, S. Singh, V. Sharma, V. P. Singh, and R. Deshmukh, Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies, Biomed. Pharmacother. Bioméd. Pharmacothérapie, vol.70, pp.283-293, 2015.

T. B. Sherer, R. Betarbet, C. M. Testa, B. B. Seo, J. R. Richardson et al., Mechanism of toxicity in rotenone models of Parkinson's disease, J. Neurosci. Off. J. Soc. Neurosci, vol.23, pp.10756-10764, 2003.

T. Shimada, H. Furuta, A. Doi, H. Ariyasu, H. Kawashima et al., Des-acyl ghrelin protects microvascular endothelial cells from oxidative stress-induced apoptosis through sirtuin 1 signaling pathway, Metabolism, vol.63, pp.469-474, 2014.

K. Shimizu, K. Ohtaki, K. Matsubara, K. Aoyama, T. Uezono et al., Carrier-mediated processes in blood--brain barrier penetration and neural uptake of paraquat, Brain Res, vol.906, pp.135-142, 2001.

A. Shin, M. Camilleri, I. Busciglio, D. Burton, S. A. Smith et al., The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus, Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc, vol.11, pp.1453-1459, 2013.

S. Shojaee, F. Sina, S. S. Banihosseini, M. H. Kazemi, R. Kalhor et al., Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays, Am. J. Hum. Genet, vol.82, pp.1375-1384, 2008.

J. Simón-sánchez, C. Schulte, J. M. Bras, M. Sharma, J. R. Gibbs et al., Genome-wide association study reveals genetic risk underlying Parkinson's disease, Nat. Genet, vol.41, pp.1308-1312, 2009.

A. B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague et al., Synuclein locus triplication causes Parkinson's disease, vol.302, p.841, 2003.

F. Sixel-döring, J. Zimmermann, A. Wegener, B. Mollenhauer, and C. Trenkwalder, The Evolution of REM Sleep Behavior Disorder in Early Parkinson Disease, 2016.

W. W. Smith, R. L. Margolis, X. Li, J. C. Troncoso, M. K. Lee et al., Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells, J. Neurosci. Off. J. Soc. Neurosci, vol.25, pp.5544-5552, 2005.

S. S. Sommer and W. A. Rocca, Prion analogues and twin studies in Parkinson's disease, Neurology, vol.46, pp.273-275, 1996.

R. Soto-otero, E. Méndez-alvarez, A. Hermida-ameijeiras, A. M. Muñoz-patiño, and J. L. Labandeira-garcia, Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease, J. Neurochem, vol.74, pp.1605-1612, 2000.

B. Spencer, R. Potkar, M. Trejo, E. Rockenstein, C. Patrick et al., Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases, J. Neurosci. Off. J. Soc. Neurosci, vol.29, pp.13578-13588, 2009.

B. A. Spengler, J. L. Biedler, and R. A. Ross, A corrected karyotype for the SH-SY5Y human neuroblastoma cell line, Cancer Genet. Cytogenet, vol.138, pp.177-178, 2002.

M. G. Spillantini, R. A. Crowther, R. Jakes, N. J. Cairns, P. L. Lantos et al., Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies, Neurosci. Lett, vol.251, pp.205-208, 1998.

M. G. Spillantini, R. A. Crowther, R. Jakes, M. Hasegawa, and M. Goedert, ?-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies, Proc. Natl. Acad. Sci, vol.95, pp.6469-6473, 1998.

M. G. Spillantini and M. Goedert, The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, Ann. N. Y. Acad. Sci, vol.920, pp.16-27, 2000.

W. Springer, T. Hoppe, E. Schmidt, and R. Baumeister, A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress, Hum. Mol. Genet, vol.14, pp.3407-3423, 2005.

H. Stachowiak, O. Wien, M. Stamelou, and K. P. Bhatia, Atypical parkinsonism: diagnosis and treatment, Neurol. Clin, vol.33, pp.39-56, 1973.

S. E. Starkstein, R. G. Robinson, R. Leiguarda, and T. J. Preziosi, Anxiety and depression in Parkinson's disease, Behav. Neurol, vol.6, pp.151-154, 1993.

K. C. Stein and H. L. True, Prion strains and amyloid polymorphism influence phenotypic variation, PLoS Pathog, vol.10, p.1004328, 2014.

M. B. Stern and A. Siderowf, Parkinson's at risk syndrome: Can Parkinson's disease be predicted?, Mov. Disord, vol.25, pp.89-93, 2010.

F. J. Steyn, V. Tolle, C. Chen, and J. Epelbaum, Neuroendocrine Regulation of Growth Hormone Secretion, Compr. Physiol, vol.6, pp.687-735, 2016.

M. G. Stokholm, E. H. Danielsen, S. J. Hamilton-dutoit, and P. Borghammer, Pathological ?synuclein in gastrointestinal tissues from prodromal Parkinson disease patients, Ann. Neurol, vol.79, pp.940-949, 2016.

G. Stores, Clinical diagnosis and misdiagnosis of sleep disorders, J. Neurol. Neurosurg. Psychiatry, vol.78, pp.1293-1297, 2007.

K. M. Strauss, L. M. Martins, H. Plun-favreau, F. P. Marx, S. Kautzmann et al., Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease, Hum. Mol. Genet, vol.14, pp.2099-2111, 2005.

L. Studer, V. Tabar, and R. D. Mckay, Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats, Nat. Neurosci, vol.1, pp.290-295, 1998.

S. R. Subramaniam, L. Vergnes, N. R. Franich, K. Reue, and M. Chesselet, Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein, 2014.

, Neurobiol. Dis, vol.70, pp.204-213

Y. Sui, K. M. Bullock, M. A. Erickson, J. Zhang, and W. A. Banks, Alpha synuclein is transported into and out of the brain by the blood-brain barrier, Peptides, vol.62, pp.197-202, 2014.

P. Svenningsson, C. Rosenblad, K. Af-edholm-arvidsson, K. Wictorin, C. Keywood et al., Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study, Brain J. Neurol, vol.138, pp.963-973, 2015.

R. Taipa, C. Pereira, I. Reis, I. Alonso, A. Bastos-lima et al., DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology, Brain J. Neurol, vol.139, pp.1680-1687, 2016.

K. Takagi, R. Legrand, A. Asakawa, H. Amitani, M. François et al., Anti-ghrelin immunoglobulins modulate ghrelin stability and its orexigenic effect in obese mice and humans, Nat. Commun, vol.4, p.2685, 2013.

H. Takeda, S. Muto, K. Nakagawa, S. Ohnishi, and M. Asaka, Rikkunshito and ghrelin secretion, Curr. Pharm. Des, vol.18, pp.4827-4838, 2012.

L. Tönges, T. Frank, L. Tatenhorst, K. A. Saal, J. C. Koch et al., Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease, Brain J. Neurol, vol.135, pp.3355-3370, 2012.

H. T. Tran, C. H. Chung, .. Iba, M. Zhang, B. Trojanowski et al., ?synuclein immunotherapy blocks uptake and templated propagation of misfolded ?synuclein and neurodegeneration, Cell Rep, vol.7, pp.2054-2065, 2014.

K. N. Tretiakoff, Contribution à l'étude de l'anatomie pathologique du locus niger de Soemmering avec quelques deductions à la pathologie des troubles musculaires et de la maladie de Parkinson, 1919.

P. A. Trimmer, M. K. Borland, P. M. Keeney, J. P. Bennett, and W. D. Parker, Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies, J. Neurochem, vol.88, pp.800-812, 2004.

J. Q. Trojanowski and V. M. Lee, Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders, Ann. N. Y. Acad. Sci, vol.924, pp.62-67, 2000.

E. Tsika, M. Kannan, C. S. Foo, .. Dikeman, D. Glauser et al., Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration, Neurobiol. Dis, vol.71, pp.345-358, 2014.

M. D. Tuttle, G. Comellas, A. J. Nieuwkoop, D. J. Covell, D. A. Berthold et al., Solid-state NMR structure of a pathogenic fibril of fulllength human ?-synuclein, Nat. Struct. Mol. Biol, vol.23, pp.409-415, 2016.

T. Tyson, J. A. Steiner, and P. Brundin, Sorting out release, uptake and processing of alphasynuclein during prion-like spread of pathology, J. Neurochem, 2015.

C. Tzoulis, G. T. Tran, T. Schwarzlmüller, K. Specht, K. Haugarvoll et al., Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations, Brain J. Neurol, vol.136, pp.2393-2404, 2013.

M. M. Unger, J. C. Möller, K. Mankel, K. M. Eggert, K. Bohne et al., Postprandial ghrelin response is reduced in patients with Parkinson's disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson's disease?, J. Neurol, vol.258, pp.982-990, 2011.

U. Ungerstedt, 6-Hydroxy-dopamine induced degeneration of central monoamine neurons, Eur. J. Pharmacol, vol.5, pp.107-110, 1968.

E. M. Valente, P. M. Abou-sleiman, V. Caputo, M. M. Muqit, K. Harvey et al., Hereditary early-onset Parkinson's disease caused by mutations in PINK1, Science, vol.304, pp.1158-1160, 2004.

E. Valera and E. Masliah, Immunotherapy for neurodegenerative diseases: focus on ?synucleinopathies, Pharmacol. Ther, vol.138, pp.311-322, 2013.

C. M. Van-duijn, M. C. Dekker, V. Bonifati, R. J. Galjaard, J. J. Houwing-duistermaat et al., PARK7, a Novel Locus for Autosomal Recessive Early-Onset Parkinsonism, on Chromosome 1p36, vol.69, pp.629-634, 2001.

S. Venneti, J. L. Robinson, S. Roy, M. T. White, J. Baccon et al., Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases, Acta Neuropathol. (Berl.), vol.122, pp.737-745, 2011.

A. Verstraeten, J. Theuns, and C. Van-broeckhoven, Progress in unraveling the genetic etiology of Parkinson disease in a genomic era, Trends Genet. TIG, vol.31, pp.140-149, 2015.

C. Vilariño-güell, C. Wider, O. A. Ross, J. C. Dachsel, J. M. Kachergus et al., VPS35 mutations in Parkinson disease, Am. J. Hum. Genet, vol.89, pp.162-167, 2011.

L. A. Volpicelli-daley, K. L. Gamble, C. E. Schultheiss, D. M. Riddle, A. B. West et al., Formation of ?-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes, Mol. Biol. Cell, vol.25, pp.4010-4023, 2014.

L. A. Volpicelli-daley, K. C. Luk, T. P. Patel, S. A. Tanik, D. M. Riddle et al., Exogenous ?-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death, Neuron, vol.72, pp.57-71, 2011.

S. Von-campenhausen, B. Bornschein, R. Wick, K. Bötzel, C. Sampaio et al., Prevalence and incidence of Parkinson's disease in Europe, Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol, vol.15, pp.473-490, 2005.

G. Walkinshaw and C. M. Waters, Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis, Neuroscience, vol.63, pp.975-987, 1994.

K. Walsh and G. Bennett, Parkinson's disease and anxiety, Postgrad. Med. J, vol.77, pp.89-93, 2001.

L. Wang, S. M. Fleming, M. Chesselet, and Y. Taché, Abnormal colonic motility in mice overexpressing human wild-type ?-synuclein, NeuroReport, vol.19, pp.873-876, 2008.

L. Wang, S. Mogami, H. Karasawa, C. Yamada, S. Yakabi et al., Preventive effect of rikkunshito on gastric motor function inhibited by l-dopa in rats, Peptides, vol.55, pp.136-144, 2014.

L. Wang, N. P. Murphy, A. Stengel, M. Goebel-stengel, D. H. Pierre et al., Ghrelin prevents levodopa-induced inhibition of gastric emptying and increases circulating levodopa in fasted rats: Ghrelin prevents l-dopa-delayed gastric emptying, Neurogastroenterol. Motil, vol.24, pp.235-245, 2012.

X. Wang and E. K. Michaelis, Selective Neuronal Vulnerability to Oxidative Stress in the Brain, Front. Aging Neurosci, vol.2, 2010.

C. D. Ward, R. C. Duvoisin, S. E. Ince, J. D. Nutt, R. Eldridge et al., Parkinson's disease in 65 pairs of twins and in a set of quadruplets, Neurology, vol.33, pp.815-815, 1983.

M. Watabe-uchida, L. Zhu, S. K. Ogawa, A. Vamanrao, and N. Uchida, Whole-brain mapping of direct inputs to midbrain dopamine neurons, Neuron, vol.74, pp.858-873, 2012.

J. C. Watts and S. B. Prusiner, Mouse models for studying the formation and propagation of prions, J. Biol. Chem, vol.289, 2014.

J. L. Webb, B. Ravikumar, J. Atkins, J. N. Skepper, and D. C. Rubinsztein, Alpha-Synuclein is degraded by both autophagy and the proteasome, J. Biol. Chem, vol.278, pp.25009-25013, 2003.

M. Wellman and A. Abizaid, Growth Hormone Secretagogue Receptor Dimers: A New Pharmacological Target. eNeuro 2, 2015.

C. H. Williams-gray, T. Foltynie, C. E. Brayne, T. W. Robbins, and R. A. Barker, Evolution of cognitive dysfunction in an incident Parkinson's disease cohort, Brain J. Neurol, vol.130, pp.1787-1798, 2007.

P. Willner, The validity of animal models of depression, Psychopharmacology (Berl.), vol.83, pp.1-16, 1984.

J. M. Wo, N. Ejskjaer, P. M. Hellström, R. A. Malik, J. C. Pezzullo et al., Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data, Aliment. Pharmacol. Ther, vol.33, pp.679-688, 2011.

D. Woolley, D. Gietzen, S. Gee, J. Magdalou, and B. Hammock, Does paraquat (PD) mimic MPP+ toxicity?, Proc. West. Pharmacol. Soc, pp.191-193, 1989.

A. M. Wren, L. J. Seal, M. A. Cohen, A. E. Brynes, G. S. Frost et al., Ghrelin enhances appetite and increases food intake in humans, J. Clin. Endocrinol. Metab, vol.86, p.5992, 2001.

X. Wu, M. L. Block, W. Zhang, L. Qin, B. Wilson et al., The role of microglia in paraquat-induced dopaminergic neurotoxicity, Antioxid. Redox Signal, vol.7, pp.654-661, 2005.

N. Xiong, J. Xiong, M. Jia, L. Liu, X. Zhang et al., The role of autophagy in Parkinson's disease: rotenone-based modeling, Behav. Brain Funct. BBF, vol.9, p.13, 2013.

L. Xu and J. Pu, Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application. Park. Dis, p.1720621, 2016.

D. Yang, Z. Liu, H. Zhang, and Q. Luo, Ghrelin protects human pulmonary artery endothelial cells against hypoxia-induced injury via PI3-kinase/Akt, Peptides, vol.42, pp.112-117, 2013.

Q. Yang, H. She, M. Gearing, E. Colla, M. Lee et al., Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy, Science, vol.323, pp.124-127, 2009.

W. L. Yang and A. Y. Sun, Paraquat-induced cell death in PC12 cells, Neurochem. Res, vol.23, pp.1387-1394, 1998.

J. Yu, H. Xu, X. Shen, and H. Jiang, Ghrelin protects MES23.5 cells against rotenone via inhibiting mitochondrial dysfunction and apoptosis, Neuropeptides, vol.56, pp.69-74, 2016.

J. Yu, H. Xu, X. Shen, and H. Jiang, Ghrelin protects MES23.5 cells against rotenone via inhibiting mitochondrial dysfunction and apoptosis, Neuropeptides, 2015.

J. J. Zarranz, J. Alegre, J. C. Gómez-esteban, E. Lezcano, R. Ros et al., The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia, Ann. Neurol, vol.55, pp.164-173, 2004.

W. J. Zetusky, J. Jankovic, and F. J. Pirozzolo, The heterogeneity of Parkinson's disease: clinical and prognostic implications, Neurology, vol.35, pp.522-526, 1985.

L. Zhang, Y. Dong, X. Xu, and Z. Xu, The role of autophagy in Parkinson's disease, Neural Regen. Res, vol.7, pp.141-145, 2012.

W. Zhang, B. Chai, J. Li, H. Wang, and M. W. Mulholland, Effect of Des-acyl Ghrelin on Adiposity and Glucose Metabolism, Endocrinology, vol.149, pp.4710-4716, 2008.

X. Zhang, M. Yin, and M. Zhang, Cell-based assays for Parkinson's disease using differentiated human LUHMES cells, Acta Pharmacol. Sin, vol.35, pp.945-956, 2014.

X. Zhu, Y. Cao, K. Voodg, and D. F. Steiner, On the Processing of Proghrelin to Ghrelin, J. Biol. Chem, vol.281, pp.38867-38870, 2006.

J. M. Zigman, S. G. Bouret, and Z. B. Andrews, Obesity Impairs the Action of the Neuroendocrine Ghrelin System, Trends Endocrinol. Metab. TEM, vol.27, pp.54-63, 2016.

J. M. Zigman, J. E. Jones, C. E. Lee, C. B. Saper, and J. K. Elmquist, Expression of ghrelin receptor mRNA in the rat and the mouse brain, J. Comp. Neurol, vol.494, pp.528-548, 2006.

A. Zimprich, S. Biskup, P. Leitner, P. Lichtner, M. Farrer et al., Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, Neuron, vol.44, pp.601-607, 2004.

P. Zizzari, R. Hassouna, D. Grouselle, J. Epelbaum, and V. Tolle, Physiological roles of preproghrelin-derived peptides in GH secretion and feeding, Peptides, vol.32, pp.2274-2282, 2011.

, Dribbling of saliva during the daytime

. .. , Loss or change in your ability to taste or smell

, Difficulty swallowing food or drink or problems with choking

. .. , Vomiting or feelings of sickness (nausea)

. .. , Constipation (less than 3 bowel movements a week) or having to strain to pass a stool (faeces)

, Bowel (fecal) incontinence

, Feeling that your bowel emptying is incomplete after having been to the toilet

, A sense of urgency to pass urine makes you rush to the toilet

. .. , Getting up regularly at night to pass urine

, Unexplained pains (not due to known conditions such as arthritis)

, Problems remembering things that have happened recently or forgetting to do things

, Loss of interest in what is happening around you or doing things

, Seeing or hearing things that you know or are told are not there

. .. , Difficulty concentrating or staying focussed

, Feeling anxious, frightened or panicky

, Feeling less interested in sex or more interested in sex

, Feeling light headed, dizzy or weak standing from sitting or lying, p.20

, Finding it difficult to stay awake during activities such as working, driving or eating, p.22

. .. , Intense, vivid dreams or frightening dreams

, Unpleasant sensations in your legs at night or while resting, and a feeling that you need to move, Talking or moving about in your sleep as if you are 'acting' out a

, Believing things are happening to you that other people say are not true, p.30

R. Abbott, R. A. Cox, M. Markus, H. Tomkins, and A. , Diet, body size and micronutrient status in Parkinson's disease, Eur. J. Clin. Nutr, vol.46, pp.879-884, 1992.

A. Abizaid, Z. Liu, Z. B. Andrews, M. Shanabrough, E. Borok et al., Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite, J. Clin. Invest, vol.116, pp.3229-3239, 2006.

R. A. Adan, J. J. Hillebrand, U. N. Danner, S. Cardona-cano, M. J. Kas et al., Neurobiology driving hyperactivity in activity-based anorexia, Curr. Top. Behav. Neurosci, vol.6, pp.229-250, 2011.

T. Akamizu and K. Kangawa, Therapeutic applications of ghrelin to cachexia utilizing its appetite-stimulating effect, Peptides, vol.32, pp.2295-2300, 2011.

R. L. Albin, A. B. Young, and J. B. Penney, The functional anatomy of basal ganglia disorders, Trends Neurosci, vol.12, pp.366-375, 1989.

H. Alzahrani and A. Venneri, Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson's disease: A systematic review, J. Neurol. Sci, vol.356, pp.32-44, 2015.

, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association, 2013.

Z. B. Andrews, D. Erion, R. Beiler, Z. Liu, A. Abizaid et al., Ghrelin Promotes and Protects Nigrostriatal Dopamine Function via a UCP2-Dependent Mitochondrial Mechanism, J. Neurosci, vol.29, pp.14057-14065, 2009.